References

Español | Other Languages

Cox NJ, Subbarao K. Influenza. Lancet. 1999 Oct
09;354(9186):1277-82.
Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal
wash antibodies associated with resistance to experimental challenge with
influenza A wild-type virus. J Clin Microbiol. 1986 Jul;24(1):157-60.
Potter CW, Oxford JS. Determinants of immunity to influenza
infection in man. Br Med Bull. 1979 Jan;35(1):69-75.
Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev
Microbiol. 1983;37:529-49.
Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ,
et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N
Engl J Med. 2009 Jun 18;360(25):2605-15.
Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A,
et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1)
influenza viruses circulating in humans. Science. 2009 Jul
10;325(5937):197-201.
Chen R, Holmes EC. The evolutionary dynamics of human influenza
B virus. J Mol Evol. 2008 Jun;66(6):655-63.
Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K.
Cocirculation of two distinct evolutionary lineages of influenza type B virus
since 1983. Virology. 1990 Mar;175(1):59-68.
McCullers JA, Saito T, Iverson AR. Multiple genotypes of
influenza B virus circulated between 1979 and 2003. J Virol. 2004
Dec;78(23):12817-28.
Ambrose CS, Levin MJ. The rationale for quadrivalent influenza
vaccines. Hum Vaccin Immunother. 2012 Jan;8(1):81-8.
Cooney MK, Fox JP, Hall CE. The Seattle Virus Watch. VI.
Observations of infections with and illness due to parainfluenza, mumps and
respiratory syncytial viruses and Mycoplasma pneumoniae. Am J Epidemiol. 1975
Jun;101(6):532-51.
Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA,
Iwane MK, et al. The underrecognized burden of influenza in young children. N
Engl J Med. 2006 Jul 06;355(1):31-40.
CDC FluView–Outpatient Illness Surveillance. Atlanta, GA: U.S.
Department of Health and Human Services, CDC; 2017; Available from: http://www.cdc.gov/flu/weekly.
Fowlkes A, Steffens A, Temte J, Di Lonardo S, McHugh L, Martin
K, et al. Incidence of medically attended influenza during pandemic and
post-pandemic seasons through the Influenza Incidence Surveillance Project,
2009-13. Lancet Respir Med. 2015 Sep;3(9):709-18.
Barker WH. Excess pneumonia and influenza associated
hospitalization during influenza epidemics in the United States, 1970-78. Am J
Public Health. 1986 Jul;76(7):761-5.
Barker WH, Mullooly JP. Impact of epidemic type A influenza in
a defined adult population. Am J Epidemiol. 1980 Dec;112(6):798-811.
Centers for Disease C, Prevention. Estimates of deaths
associated with seasonal influenza — United States, 1976-2007. MMWR Morb
Mortal Wkly Rep. 2010 Aug 27;59(33):1057-62.
Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact
of respiratory virus infections on persons with chronic underlying conditions.
JAMA. 2000 Jan 26;283(4):499-505.
Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Jr., Griffin MR.
The effect of influenza on hospitalizations, outpatient visits, and courses of
antibiotics in children. N Engl J Med. 2000 Jan 27;342(4):225-31.
O’Brien MA, Uyeki TM, Shay DK, Thompson WW, Kleinman K, McAdam
A, et al. Incidence of outpatient visits and hospitalizations related to
influenza in infants and young children. Pediatrics. 2004 Mar;113(3 Pt
1):585-93.
Keren R, Zaoutis TE, Bridges CB, Herrera G, Watson BM, Wheeler
AB, et al. Neurological and neuromuscular disease as a risk factor for
respiratory failure in children hospitalized with influenza infection. JAMA.
2005 Nov 02;294(17):2188-94.
Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E,
Jackson LA, et al. Influenza- and RSV-associated hospitalizations among
adults. Vaccine. 2007 Jan 15;25(5):846-55.
Wong KK, Jain S, Blanton L, Dhara R, Brammer L, Fry AM, et al.
Influenza-associated pediatric deaths in the United States, 2004-2012.
Pediatrics. 2013 Nov;132(5):796-804.
Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson
LJ, et al. Mortality associated with influenza and respiratory syncytial virus
in the United States. JAMA. 2003 Jan 08;289(2):179-86.
Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox
NJ, et al. Influenza-associated hospitalizations in the United States. JAMA.
2004 Sep 15;292(11):1333-40.
Thompson WW, Weintraub E, Dhankhar P, Cheng PY, Brammer L,
Meltzer MI, et al. Estimates of US influenza-associated deaths made using four
different methods. Influenza Other Respir Viruses. 2009 Jan;3(1):37-49.
Reed C, Chaves SS, Daily Kirley P, Emerson R, Aragon D, Hancock
EB, et al. Estimating influenza disease burden from population-based
surveillance data in the United States. PLoS One. 2015;10(3):e0118369.
CDC. Estimated Influenza Illnesses, Medical Visits,
Hospitalizations, and Deaths Averted by Vaccination in the United States.
Atlanta, GA: CDC; 2017 [cited 2017 June 7, 2017];
Poehling KA, Edwards KM, Griffin MR, Szilagyi PG, Staat MA,
Iwane MK, et al. The burden of influenza in young children, 2004-2009.
Pediatrics. 2013 Feb;131(2):207-16.
Bourgeois FT, Valim C, Wei JC, McAdam AJ, Mandl KD. Influenza
and other respiratory virus-related emergency department visits among young
children. Pediatrics. 2006 Jul;118(1):e1-8.
Jules A, Grijalva CG, Zhu Y, Talbot HK, Williams JV, Poehling
KA, et al. Influenza-related hospitalization and ED visits in children less
than 5 years: 2000-2011. Pediatrics. 2015 Jan;135(1):e66-74.
Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL,
DeStefano F, et al. Influenza and the rates of hospitalization for respiratory
disease among infants and young children. N Engl J Med. 2000 Jan
27;342(4):232-9.
Mullooly JP, Barker WH. Impact of type A influenza on children:
a retrospective study. Am J Public Health. 1982 Sep;72(9):1008-16.
Ampofo K, Gesteland PH, Bender J, Mills M, Daly J, Samore M, et
al. Epidemiology, complications, and cost of hospitalization in children with
laboratory-confirmed influenza infection. Pediatrics. 2006
Dec;118(6):2409-17.
Coffin SE, Zaoutis TE, Rosenquist AB, Heydon K, Herrera G,
Bridges CB, et al. Incidence, complications, and risk factors for prolonged
stay in children hospitalized with community-acquired influenza. Pediatrics.
2007 Apr;119(4):740-8.
Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner
C, et al. Hospitalizations associated with influenza and respiratory syncytial
virus in the United States, 1993-2008. Clin Infect Dis. 2012
May;54(10):1427-36.
Schrag SJ, Shay DK, Gershman K, Thomas A, Craig AS, Schaffner
W, et al. Multistate surveillance for laboratory-confirmed,
influenza-associated hospitalizations in children: 2003-2004. Pediatr Infect
Dis J. 2006 May;25(5):395-400.
Iwane MK, Edwards KM, Szilagyi PG, Walker FJ, Griffin MR,
Weinberg GA, et al. Population-based surveillance for hospitalizations
associated with respiratory syncytial virus, influenza virus, and
parainfluenza viruses among young children. Pediatrics. 2004
Jun;113(6):1758-64.
Miller EK, Griffin MR, Edwards KM, Weinberg GA, Szilagyi PG,
Staat MA, et al. Influenza burden for children with asthma. Pediatrics. 2008
Jan;121(1):1-8.
Neuzil KM, Wright PF, Mitchel EF, Jr., Griffin MR. The burden
of influenza illness in children with asthma and other chronic medical
conditions. J Pediatr. 2000 Dec;137(6):856-64.
Finelli L, Fiore A, Dhara R, Brammer L, Shay DK, Kamimoto L, et
al. Influenza-associated pediatric mortality in the United States: increase of
Staphylococcus aureus coinfection. Pediatrics. 2008 Oct;122(4):805-11.
Bhat N, Wright JG, Broder KR, Murray EL, Greenberg ME, Glover
MJ, et al. Influenza-associated deaths among children in the United States,
2003-2004. N Engl J Med. 2005 Dec 15;353(24):2559-67.
CDC. FluView. Influenza-Associated Pediatric Mortality.
Atlanta, GA: CDC; 2017 [cited 2017 21 April]; Available from: https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html.
D’Mello T, Brammer L, Blanton L, Kniss K, Smith S, Mustaquim D,
et al. Update: Influenza activity–United States, September 28, 2014-February
21, 2015. MMWR Morb Mortal Wkly Rep. 2015 Mar 06;64(8):206-12.
Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW,
Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the
US: measuring disease burden and costs. Vaccine. 2007 Jun
28;25(27):5086-96.
Campbell DS, Rumley MH. Cost-effectiveness of the influenza
vaccine in a healthy, working-age population. J Occup Environ Med. 1997
May;39(5):408-14.
Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ,
Cox NJ, et al. Effectiveness and cost-benefit of influenza vaccination of
healthy working adults: A randomized controlled trial. JAMA. 2000 Oct
04;284(13):1655-63.
Olsen GW, Burris JM, Burlew MM, Steinberg ME, Patz NV,
Stoltzfus JA, et al. Absenteeism among employees who participated in a
workplace influenza immunization program. J Occup Environ Med. 1998
Apr;40(4):311-6.
Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza
vaccination in healthy, working adults: an economic analysis based on the
results of a clinical trial of trivalent live attenuated influenza virus
vaccine. Vaccine. 2003 May 16;21(17-18):2207-17.
Shrestha SS, Swerdlow DL, Borse RH, Prabhu VS, Finelli L,
Atkins CY, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in
the United States (April 2009-April 2010). Clin Infect Dis. 2011 Jan 01;52
Suppl 1:S75-82.
Centers for Disease C, Prevention. Update: influenza activity –
United States, 2009-10 season. MMWR Morb Mortal Wkly Rep. 2010 Jul
30;59(29):901-8.
Epperson S, Blanton L, Kniss K, Mustaquim D, Steffens C, Wallis
T, et al. Influenza activity – United States, 2013-14 season and composition
of the 2014-15 influenza vaccines. MMWR Morb Mortal Wkly Rep. 2014 Jun
06;63(22):483-90.
Ramos JM, Garcia-Navarro MM, Gonzalez de la Aleja MP,
Sanchez-Martinez R, Gimeno-Gascon A, Reus S, et al. Seasonal influenza in
octogenarians and nonagenarians admitted to a general hospital: epidemiology,
clinical presentation and prognostic factors. Rev Esp Quimioter. 2016
Dec;29(6):296-301.
Goodnight WH, Soper DE. Pneumonia in pregnancy. Crit Care Med.
2005 Oct;33(10 Suppl):S390-7.
Sokolow LZ, Naleway AL, Li DK, Shifflett P, Reynolds S,
Henninger ML, et al. Severity of influenza and noninfluenza acute respiratory
illness among pregnant women, 2010-2012. Am J Obstet Gynecol. 2015
Feb;212(2):202 e1-11.
Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact
of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J
Epidemiol. 1998 Dec 01;148(11):1094-102.
Kort BA, Cefalo RC, Baker VV. Fatal influenza A pneumonia in
pregnancy. Am J Perinatol. 1986 Jul;3(3):179-82.
Dodds L, McNeil SA, Fell DB, Allen VM, Coombs A, Scott J, et
al. Impact of influenza exposure on rates of hospital admissions and physician
visits because of respiratory illness among pregnant women. CMAJ. 2007 Feb
13;176(4):463-8.
Harris J. Influenza occurring in pregnant women: a statistical
study of thirteen hundred and fifty cases. JAMA. 1919;72:978-80.
Louie JK, Acosta M, Jamieson DJ, Honein MA. Severe 2009 H1N1
influenza in pregnant and postpartum women in California. N Engl J Med. 2009
Jan 7;362(1):27-35.
Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL,
Biggerstaff MS, et al. H1N1 2009 influenza virus infection during pregnancy in
the USA. Lancet. 2009 Aug 08;374(9688):451-8.
Freeman DW, Barno A. Deaths from Asian influenza associated
with pregnancy. Am J Obstet Gynecol. 1959 Dec;78:1172-5.
Centers for Disease C, Prevention. 2009 pandemic influenza A
(H1N1) in pregnant women requiring intensive care – New York City, 2009. MMWR
Morb Mortal Wkly Rep. 2010 Mar 26;59(11):321-6.
Creanga AA, Johnson TF, Graitcer SB, Hartman LK, Al-Samarrai T,
Schwarz AG, et al. Severity of 2009 pandemic influenza A (H1N1) virus
infection in pregnant women. Obstet Gynecol. 2010 Apr;115(4):717-26.
Mosby LG, Rasmussen SA, Jamieson DJ. 2009 pandemic influenza A
(H1N1) in pregnancy: a systematic review of the literature. Am J Obstet
Gynecol. 2011 Jul;205(1):10-8.
Siston AM, Rasmussen SA, Honein MA, Fry AM, Seib K, Callaghan
WM, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women
in the United States. JAMA. 2010 Apr 21;303(15):1517-25.
Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. N
Engl J Med. 2014 Jun 05;370(23):2211-8.
Cox S, Posner SF, McPheeters M, Jamieson DJ, Kourtis AP, Meikle
S. Hospitalizations with respiratory illness among pregnant women during
influenza season. Obstet Gynecol. 2006 Jun;107(6):1315-22.
Haberg SE, Trogstad L, Gunnes N, Wilcox AJ, Gjessing HK,
Samuelsen SO, et al. Risk of fetal death after pandemic influenza virus
infection or vaccination. N Engl J Med. 2013 Jan 24;368(4):333-40.
Pierce M, Kurinczuk JJ, Spark P, Brocklehurst P, Knight M,
Ukoss. Perinatal outcomes after maternal 2009/H1N1 infection: national cohort
study. BMJ. 2011 Jun 14;342:d3214.
Irving WL, James DK, Stephenson T, Laing P, Jameson C, Oxford
JS, et al. Influenza virus infection in the second and third trimesters of
pregnancy: a clinical and seroepidemiological study. BJOG. 2000
Oct;107(10):1282-9.
Griffiths PD, Ronalds CJ, Heath RB. A prospective study of
influenza infections during pregnancy. J Epidemiol Community Health. 1980
Jun;34(2):124-8.
Hartert TV, Neuzil KM, Shintani AK, Mitchel EF, Jr., Snowden
MS, Wood LB, et al. Maternal morbidity and perinatal outcomes among pregnant
women with respiratory hospitalizations during influenza season. Am J Obstet
Gynecol. 2003 Dec;189(6):1705-12.
Edwards MJ. Review: Hyperthermia and fever during pregnancy.
Birth Defects Res A Clin Mol Teratol. 2006 Jul;76(7):507-16.
Luteijn JM, Brown MJ, Dolk H. Influenza and congenital
anomalies: a systematic review and meta-analysis. Hum Reprod. 2014
Apr;29(4):809-23.
Moretti ME, Bar-Oz B, Fried S, Koren G. Maternal hyperthermia
and the risk for neural tube defects in offspring: systematic review and
meta-analysis. Epidemiology. 2005 Mar;16(2):216-9.
Oster ME, Riehle-Colarusso T, Alverson CJ, Correa A.
Associations between maternal fever and influenza and congenital heart
defects. J Pediatr. 2011 Jun;158(6):990-5.
Shahrukh Hashmi S, Gallaway MS, Waller DK, Langlois PH, Hecht
JT, National Birth Defects Prevention S. Maternal fever during early pregnancy
and the risk of oral clefts. Birth Defects Res A Clin Mol Teratol. 2010
Mar;88(3):186-94.
Botto LD, Erickson JD, Mulinare J, Lynberg MC, Liu Y. Maternal
fever, multivitamin use, and selected birth defects: evidence of interaction?
Epidemiology. 2002 Jul;13(4):485-8.
Burney LE. Influenza immunization: Statement. Public Health
Rep. 1960 Oct;75(10):944.
Garg S, Jain S, Dawood FS, Jhung M, Perez A, D’Mello T, et al.
Pneumonia among adults hospitalized with laboratory-confirmed seasonal
influenza virus infection-United States, 2005-2008. BMC Infect Dis. 2015 Aug
26;15:369.
Sheth AN, Althoff KN, Brooks JT. Influenza susceptibility,
severity, and shedding in HIV-infected adults: a review of the literature.
Clin Infect Dis. 2011 Jan 15;52(2):219-27.
Perez CM, Dominguez MI, Ceballos ME, Moreno C, Labarca JA,
Rabagliati R, et al. Pandemic influenza A (H1N1) in HIV-1-infected patients.
AIDS. 2010 Nov 27;24(18):2867-9.
Riera M, Payeras A, Marcos MA, Viasus D, Farinas MC, Segura F,
et al. Clinical presentation and prognosis of the 2009 H1N1 influenza A
infection in HIV-1-infected patients: a Spanish multicenter study. AIDS. 2010
Oct 23;24(16):2461-7.
Martinez E, Marcos MA, Hoyo-Ulloa I, Anton A, Sanchez M,
Vilella A, et al. Influenza A H1N1 in HIV-infected adults. HIV Med. 2011
Apr;12(4):236-45.
Neuzil KM, Reed GW, Mitchel EF, Jr., Griffin MR.
Influenza-associated morbidity and mortality in young and middle-aged women.
JAMA. 1999 Mar 10;281(10):901-7.
Neuzil KM, Coffey CS, Mitchel EF, Jr., Griffin MR.
Cardiopulmonary hospitalizations during influenza season in adults and
adolescents with advanced HIV infection. J Acquir Immune Defic Syndr. 2003 Nov
01;34(3):304-7.
Cohen C, Moyes J, Tempia S, Groom M, Walaza S, Pretorius M, et
al. Severe influenza-associated respiratory infection in high HIV prevalence
setting, South Africa, 2009-2011. Emerg Infect Dis. 2013
Nov;19(11):1766-74.
Cohen C, Walaza S, Moyes J, Groome M, Tempia S, Pretorius M, et
al. Epidemiology of severe acute respiratory illness (SARI) among adults and
children aged >/=5 years in a high HIV-prevalence setting, 2009-2012. PLoS
One. 2015;10(2):e0117716.
Lin JC, Nichol KL. Excess mortality due to pneumonia or
influenza during influenza seasons among persons with acquired
immunodeficiency syndrome. Arch Intern Med. 2001 Feb 12;161(3):441-6.
Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J,
et al. Hospitalized patients with 2009 H1N1 influenza in the United States,
April-June 2009. N Engl J Med. 2009 Nov 12;361(20):1935-44.
Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix
J, et al. Critically ill patients with 2009 influenza A(H1N1) infection in
Canada. JAMA. 2009 Nov 04;302(17):1872-9.
Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, et
al. Factors associated with death or hospitalization due to pandemic 2009
influenza A(H1N1) infection in California. JAMA. 2009 Nov
04;302(17):1896-902.
Morgan OW, Bramley A, Fowlkes A, Freedman DS, Taylor TH,
Gargiullo P, et al. Morbid obesity as a risk factor for hospitalization and
death due to 2009 pandemic influenza A(H1N1) disease. PLoS One. 2010 Mar
15;5(3):e9694.
Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory
hospitalizations during influenza seasons in Ontario, Canada: a cohort study.
Clin Infect Dis. 2011 Sep;53(5):413-21.
Coleman LA, Waring SC, Irving SA, Vandermause M, Shay DK,
Belongia EA. Evaluation of obesity as an independent risk factor for medically
attended laboratory-confirmed influenza. Influenza Other Respir Viruses. 2013
Mar;7(2):160-7.
Webb SA, Pettila V, Seppelt I, Bellomo R, Bailey M, Cooper DJ,
et al. Critical care services and 2009 H1N1 influenza in Australia and New
Zealand. N Engl J Med. 2009 Nov 12;361(20):1925-34.
Baker MG, Wilson N, Huang QS, Paine S, Lopez L, Bandaranayake
D, et al. Pandemic influenza A(H1N1)v in New Zealand: the experience from
April to August 2009. Euro Surveill. 2009 Aug 27;14(34).
La Ruche G, Tarantola A, Barboza P, Vaillant L, Gueguen J,
Gastellu-Etchegorry M, et al. The 2009 pandemic H1N1 influenza and indigenous
populations of the Americas and the Pacific. Euro Surveill. 2009 Oct
22;14(42).
Centers for Disease C, Prevention. Deaths related to 2009
pandemic influenza A (H1N1) among American Indian/Alaska Natives – 12 states,
2009. MMWR Morb Mortal Wkly Rep. 2009 Dec 11;58(48):1341-4.
Hutchins SS, Fiscella K, Levine RS, Ompad DC, McDonald M.
Protection of racial/ethnic minority populations during an influenza pandemic.
Am J Public Health. 2009 Oct;99 Suppl 2:S261-70.
Zarychanski R, Stuart TL, Kumar A, Doucette S, Elliott L,
Kettner J, et al. Correlates of severe disease in patients with 2009 pandemic
influenza (H1N1) virus infection. CMAJ. 2010 Feb 23;182(3):257-64.
Groom AV, Jim C, Laroque M, Mason C, McLaughlin J, Neel L, et
al. Pandemic influenza preparedness and vulnerable populations in tribal
communities. Am J Public Health. 2009 Oct;99 Suppl 2:S271-8.
Hennessy TW, Bruden D, Castrodale L, Komatsu K, Erhart LM,
Thompson D, et al. A case-control study of risk factors for death from 2009
pandemic influenza A(H1N1): is American Indian racial status an independent
risk factor? Epidemiol Infect. 2016 Jan;144(2):315-24.
Nichol KL. Heterogeneity of influenza case definitions and
implications for interpreting and comparing study results. Vaccine. 2006 Nov
10;24(44-46):6726-8.
Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS.
Evidence of bias in estimates of influenza vaccine effectiveness in seniors.
Int J Epidemiol. 2006 Apr;35(2):337-44.
Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA.
Mortality benefits of influenza vaccination in elderly people: an ongoing
controversy. Lancet Infect Dis. 2007 Oct;7(10):658-66.
Talbot HK, Nian H, Chen Q, Zhu Y, Edwards KM, Griffin MR.
Evaluating the case-positive, control test-negative study design for influenza
vaccine effectiveness for the frailty bias. Vaccine. 2016 Apr
04;34(15):1806-9.
Ferdinands JM, Shay DK. Magnitude of potential biases in a
simulated case-control study of the effectiveness of influenza vaccination.
Clin Infect Dis. 2012 Jan 01;54(1):25-32.
Jackson ML, Rothman KJ. Effects of imperfect test sensitivity
and specificity on observational studies of influenza vaccine effectiveness.
Vaccine. 2015 Mar 10;33(11):1313-6.
Chang DH, Bednarczyk RA, Becker ER, Hockenberry JM, Weiss PS,
Orenstein WA, et al. Trends in U.S. hospitalizations and inpatient deaths from
pneumonia and influenza, 1996-2011. Vaccine. 2016 Jan 20;34(4):486-94.
Oxford JS, Schild GC, Potter CW, Jennings R. The specificity
of the anti-haemagglutinin antibody response induced in man by inactivated
influenza vaccines and by natural infection. J Hyg (Lond). 1979
Feb;82(1):51-61.
Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of
inactivated and cold-adapted vaccines against influenza A infection, 1985 to
1990: the pediatric experience. Pediatr Infect Dis J. 2001
Aug;20(8):733-40.
Hirota Y, Kaji M, Ide S, Kajiwara J, Kataoka K, Goto S, et al.
Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness.
Vaccine. 1997 Jun;15(9):962-7.
La Montagne JR, Noble GR, Quinnan GV, Curlin GT, Blackwelder
WC, Smith JI, et al. Summary of clinical trials of inactivated influenza
vaccine – 1978. Rev Infect Dis. 1983 Jul-Aug;5(4):723-36.
He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, et
al. Cellular immune responses in children and adults receiving inactivated or
live attenuated influenza vaccines. J Virol. 2006 Dec;80(23):11756-66.
Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M,
et al. Antibody landscapes after influenza virus infection or vaccination.
Science. 2014 Nov 21;346(6212):996-1000.
Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy
studies of influenza vaccines: effect of end points used and characteristics
of vaccine failures. J Infect Dis. 2011 May 01;203(9):1309-15.
King JC, Jr., Lichenstein R, Magder LS. Relationship of
influenza vaccine match and use rate to medically attended acute respiratory
illnesses in older residents of Maryland. November 13, 2012. Vaccine. 2013 Jan
21;31(5):839-44.
Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A,
Foust A, et al. Effectiveness of inactivated influenza vaccines varied
substantially with antigenic match from the 2004-2005 season to the 2006-2007
season. J Infect Dis. 2009 Jan 15;199(2):159-67.
Dean AS, Moffatt CR, Rosewell A, Dwyer DE, Lindley RI, Booy R,
et al. Incompletely matched influenza vaccine still provides protection in
frail elderly. Vaccine. 2010 Jan 08;28(3):864-7.
Kelly HA, Sullivan SG, Grant KA, Fielding JE. Moderate
influenza vaccine effectiveness with variable effectiveness by match between
circulating and vaccine strains in Australian adults aged 20-64 years,
2007-2011. Influenza Other Respir Viruses. 2013 Sep;7(5):729-37.
Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A,
Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated
with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in
circulating viruses. PLoS One. 2014;9(3):e92153.
Beran J, Peeters M, Dewe W, Raupachova J, Hobzova L, Devaster
JM. Immunogenicity and safety of quadrivalent versus trivalent inactivated
influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis.
2013;13:224.
Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C,
Peeters M, et al. A randomized trial of candidate inactivated quadrivalent
influenza vaccine versus trivalent influenza vaccines in children aged 3-17
years. J Infect Dis. 2013 Jun 15;207(12):1878-87.
Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, et
al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent
influenza vaccine candidate versus inactivated trivalent influenza vaccine: a
phase III, randomized trial in adults aged >/=18 years. BMC Infect Dis.
2013;13:343.
Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA,
McNeil S, Reisinger KS, et al. Immunogenicity and safety of an inactivated
quadrivalent influenza vaccine candidate: a phase III randomized controlled
trial in children. J Infect Dis. 2013 Aug 15;208(4):544-53.
Pepin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M.
Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in
adults. Vaccine. 2013 Nov 12;31(47):5572-8.
Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders
SD, Decker MD. Safety and immunogenicity of an inactivated quadrivalent
influenza vaccine in children 6 months through 8 years of age. Pediatr Infect
Dis J. 2014 Jun;33(6):630-6.
Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C,
Chandrasekaran V, Dewe W, et al. Immunogenicity, reactogenicity, and safety of
inactivated quadrivalent influenza vaccine candidate versus inactivated
trivalent influenza vaccine in healthy adults aged >/=18 years: a phase
III, randomized trial. Vaccine. 2014 Mar 14;32(13):1480-7.
Gorse GJ, Falsey AR, Ozol-Godfrey A, Landolfi V, Tsang PH.
Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in
adults. Vaccine. 2015 Feb 25;33(9):1151-9.
Treanor JT, Albano FR, Sawlwin DC, Graves Jones A, Airey J,
Formica N, et al. Immunogenicity and safety of a quadrivalent inactivated
influenza vaccine compared with two trivalent inactivated influenza vaccines
containing alternate B strains in adults: A phase 3, randomized noninferiority
study. Vaccine. 2017 Apr 04;35(15):1856-64.
McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M,
Murthy K, et al. Influenza vaccine effectiveness in the United States during
2012-2013: variable protection by age and virus type. J Infect Dis. 2015 May
15;211(10):1529-40.
Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML,
Belongia EA, et al. Influenza vaccine effectiveness in the 2011-2012 season:
protection against each circulating virus and the effect of prior vaccination
on estimates. Clin Infect Dis. 2014 Feb;58(3):319-27.
Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M,
Izu A, Groth N, et al. Clinical efficacy of cell culture-derived and
egg-derived inactivated subunit influenza vaccines in healthy adults. Clin
Infect Dis. 2010 Nov 01;51(9):997-1004.
Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K,
Lindblad N, et al. Efficacy of inactivated split-virus influenza vaccine
against culture-confirmed influenza in healthy adults: a prospective,
randomized, placebo-controlled trial. J Infect Dis. 2009 Dec
15;200(12):1861-9.
Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB,
et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent
inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect
Dis. 2006 Oct 15;194(8):1032-9.
Allison MA, Daley MF, Crane LA, Barrow J, Beaty BL, Allred N,
et al. Influenza vaccine effectiveness in healthy 6- to 21-month-old children
during the 2003-2004 season. J Pediatr. 2006 Dec;149(6):755-62.
Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M,
France EK. Effectiveness of the 2003-2004 influenza vaccine among children 6
months to 8 years of age, with 1 vs 2 doses. Pediatrics. 2005
Jul;116(1):153-9.
Eisenberg KW, Szilagyi PG, Fairbrother G, Griffin MR, Staat M,
Shone LP, et al. Vaccine effectiveness against laboratory-confirmed influenza
in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza
seasons. Pediatrics. 2008 Nov;122(5):911-9.
Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D,
Schmitt HJ, et al. Oil-in-water emulsion adjuvant with influenza vaccine in
young children. N Engl J Med. 2011 Oct 13;365(15):1406-16.
Clover RD, Crawford S, Glezen WP, Taber LH, Matson CC, Couch
RB. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1)
by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect
Dis. 1991 Feb;163(2):300-4.
Hoberman A, Greenberg DP, Paradise JL, Rockette HE, Lave JR,
Kearney DH, et al. Effectiveness of inactivated influenza vaccine in
preventing acute otitis media in young children: a randomized controlled
trial. JAMA. 2003 Sep 24;290(12):1608-16.
Clements DA, Langdon L, Bland C, Walter E. Influenza A vaccine
decreases the incidence of otitis media in 6- to 30-month-old children in day
care. Arch Pediatr Adolesc Med. 1995 Oct;149(10):1113-7.
Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen
P. Influenza vaccination in the prevention of acute otitis media in children.
Am J Dis Child. 1991 Apr;145(4):445-8.
Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and
effectiveness of influenza vaccines: a systematic review and meta-analysis.
Lancet Infect Dis. 2012 Jan;12(1):36-44.
Petrie JG, Cheng C, Malosh RE, VanWormer JJ, Flannery B,
Zimmerman RK, et al. Illness Severity and Work Productivity Loss Among Working
Adults With Medically Attended Acute Respiratory Illnesses: US Influenza
Vaccine Effectiveness Network 2012-2013. Clin Infect Dis. 2016 Feb
15;62(4):448-55.
Reber AJ, Chirkova T, Kim JH, Cao W, Biber R, Shay DK, et al.
Immunosenescence and Challenges of Vaccination against Influenza in the Aging
Population. Aging Dis. 2012 Feb;3(1):68-90.
Goodwin K, Viboud C, Simonsen L. Antibody response to
influenza vaccination in the elderly: a quantitative review. Vaccine. 2006 Feb
20;24(8):1159-69.
Dunning AJ, DiazGranados CA, Voloshen T, Hu B, Landolfi VA,
Talbot HK. Correlates of Protection against Influenza in the Elderly: Results
from an Influenza Vaccine Efficacy Trial. Clin Vaccine Immunol. 2016 Jan
13;23(3):228-35.
Gross PA, Weksler ME, Quinnan GV, Jr., Douglas RG, Jr.,
Gaerlan PF, Denning CR. Immunization of elderly people with two doses of
influenza vaccine. J Clin Microbiol. 1987 Sep;25(9):1763-5.
Feery BJ, Cheyne IM, Hampson AW, Atkinson MI. Antibody
response to one and two doses of influenza virus subunit vaccine. Med J Aust.
1976 Feb 14;1(7):186, 8-9.
Levine M, Beattie BL, McLean DM. Comparison of one- and
two-dose regimens of influenza vaccine for elderly men. CMAJ. 1987 Oct
15;137(8):722-6.
Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ,
Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A
randomized double-blind placebo-controlled trial. JAMA. 1994 Dec
07;272(21):1661-5.
Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E,
Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly.
Cochrane Database Syst Rev. 2010 Feb 17(2):CD004876.
Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS,
Osterhaus AD. Cochrane re-arranged: support for policies to vaccinate elderly
people against influenza. Vaccine. 2013 Dec 05;31(50):6030-3.
Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER.
Effectiveness of seasonal influenza vaccine in community-dwelling elderly
people: a meta-analysis of test-negative design case-control studies. Lancet
Infect Dis. 2014 Dec;14(12):1228-39.
Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The
efficacy of influenza vaccine in elderly persons. A meta-analysis and review
of the literature. Ann Intern Med. 1995 Oct 01;123(7):518-27.
Hak E, Nordin J, Wei F, Mullooly J, Poblete S, Strikas R, et
al. Influence of high-risk medical conditions on the effectiveness of
influenza vaccination among elderly members of 3 large managed-care
organizations. Clin Infect Dis. 2002 Aug 15;35(4):370-7.
Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW,
Patriarca PA, et al. Influenza vaccination programs for elderly persons:
cost-effectiveness in a health maintenance organization. Ann Intern Med. 1994
Dec 15;121(12):947-52.
Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E.
Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J
Med. 2007 Oct 04;357(14):1373-81.
Nordin J, Mullooly J, Poblete S, Strikas R, Petrucci R, Wei F,
et al. Influenza vaccine effectiveness in preventing hospitalizations and
deaths in persons 65 years or older in Minnesota, New York, and Oregon: data
from 3 health plans. J Infect Dis. 2001 Sep 15;184(6):665-70.
Chiu PJ, Chen CH, Chih YC. Effectiveness of the influenza
vaccination program for the elderly in Taiwan. Vaccine. 2013 Jan
11;31(4):632-8.
Simonsen L, Viboud C, Taylor RJ. Effectiveness of influenza
vaccination. N Engl J Med. 2007 Dec 27;357(26):2729-30; author reply
30-1.
Jackson LA, Nelson JC, Benson P, Neuzil KM, Reid RJ, Psaty BM,
et al. Functional status is a confounder of the association of influenza
vaccine and risk of all cause mortality in seniors. Int J Epidemiol. 2006
Apr;35(2):345-52.
Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C,
Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly
people: a systematic review. Lancet. 2005 Oct 01;366(9492):1165-74.
Nelson JC, Jackson ML, Jackson LA. Effectiveness of influenza
vaccination. N Engl J Med. 2007 Dec 27;357(26):2728-9; author reply 30-1.
Wong K, Campitelli MA, Stukel TA, Kwong JC. Estimating
influenza vaccine effectiveness in community-dwelling elderly patients using
the instrumental variable analysis method. Arch Intern Med. 2012 Mar
26;172(6):484-91.
Baxter R, Ray GT, Fireman BH. Effect of influenza vaccination
on hospitalizations in persons aged 50 years and older. Vaccine. 2010 Oct
21;28(45):7267-72.
Fireman B, Lee J, Lewis N, Bembom O, van der Laan M, Baxter R.
Influenza vaccination and mortality: differentiating vaccine effects from
bias. Am J Epidemiol. 2009 Sep 01;170(5):650-6.
Kwong JC, Campitelli MA, Gubbay JB, Peci A, Winter AL, Olsha
R, et al. Vaccine effectiveness against laboratory-confirmed influenza
hospitalizations among elderly adults during the 2010-2011 season. Clin Infect
Dis. 2013 Sep;57(6):820-7.
VanWormer JJ, Sundaram ME, Meece JK, Belongia EA. A
cross-sectional analysis of symptom severity in adults with influenza and
other acute respiratory illness in the outpatient setting. BMC Infect Dis.
2014 May 01;14:231.
Arriola CS, Anderson EJ, Baumbach J, Bennett N, Bohm S, Hill
M, et al. Does Influenza Vaccination Modify Influenza Severity? Data on Older
Adults Hospitalized With Influenza During the 2012-2013 Season in the United
States. J Infect Dis. 2015 Oct 15;212(8):1200-8.
Arriola CS, Garg S, Anderson EJ, Ryan PA, George A, Zansky SM,
et al. Influenza vaccination modifies disease severity among
community-dwelling adults hospitalized with influenza. Clin Infect Dis. 2017
May 19.
Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine
effectiveness among elderly nursing home residents: a cohort study. Am J
Epidemiol. 2001 Jul 15;154(2):155-60.
Ohmit SE, Arden NH, Monto AS. Effectiveness of inactivated
influenza vaccine among nursing home residents during an influenza type A
(H3N2) epidemic. J Am Geriatr Soc. 1999 Feb;47(2):165-71.
Rivetti D, Jefferson T, Thomas R, Rudin M, Rivetti A, Di
Pietrantonj C, et al. Vaccines for preventing influenza in the elderly.
Cochrane Database Syst Rev. 2006 Jul 19(3):CD004876.
Coles FB, Balzano GJ, Morse DL. An outbreak of influenza A
(H3N2) in a well immunized nursing home population. J Am Geriatr Soc. 1992
Jun;40(6):589-92.
Libow LS, Neufeld RR, Olson E, Breuer B, Starer P. Sequential
outbreak of influenza A and B in a nursing home: efficacy of vaccine and
amantadine. J Am Geriatr Soc. 1996 Oct;44(10):1153-7.
Englund JA, Mbawuike IN, Hammill H, Holleman MC, Baxter BD,
Glezen WP. Maternal immunization with influenza or tetanus toxoid vaccine for
passive antibody protection in young infants. J Infect Dis. 1993
Sep;168(3):647-56.
Reuman PD, Ayoub EM, Small PA. Effect of passive maternal
antibody on influenza illness in children: a prospective study of influenza A
in mother-infant pairs. Pediatr Infect Dis J. 1987 Apr;6(4):398-403.
Helmig RB, Maimburg RD, Erikstrup C, Nielsen HS, Petersen OB,
Nielsen LP, et al. Antibody response to influenza A(H1N1)pdm09 in vaccinated,
serologically infected and unaffected pregnant women and their newborns. Acta
Obstet Gynecol Scand. 2015 Aug;94(8):833-9.
Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et
al. Effectiveness of maternal influenza immunization in mothers and infants. N
Engl J Med. 2008 Oct 09;359(15):1555-64.
Madhi SA, Nunes MC, Cutland CL. Influenza vaccination of
pregnant women and protection of their infants. N Engl J Med. 2014 Dec
11;371(24):2340.
Tapia MD, Sow SO, Tamboura B, Teguete I, Pasetti MF, Kodio M,
et al. Maternal immunisation with trivalent inactivated influenza vaccine for
prevention of influenza in infants in Mali: a prospective, active-controlled,
observer-blind, randomised phase 4 trial. Lancet Infect Dis. 2016
Sep;16(9):1026-35.
Steinhoff MC, Katz J, Englund JA, Khatry SK, Shrestha L,
Kuypers J, et al. Year-round influenza immunisation during pregnancy in Nepal:
a phase 4, randomised, placebo-controlled trial. Lancet Infect Dis. 2017 May
15.
Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vazquez M.
Influenza vaccine given to pregnant women reduces hospitalization due to
influenza in their infants. Clin Infect Dis. 2010 Dec 15;51(12):1355-61.
Eick AA, Uyeki TM, Klimov A, Hall H, Reid R, Santosham M, et
al. Maternal influenza vaccination and effect on influenza virus infection in
young infants. Arch Pediatr Adolesc Med. 2011 Feb;165(2):104-11.
Poehling KA, Szilagyi PG, Staat MA, Snively BM, Payne DC,
Bridges CB, et al. Impact of maternal immunization on influenza
hospitalizations in infants. Am J Obstet Gynecol. 2011 Jun;204(6 Suppl
1):S141-8.
Thompson MG, Li DK, Shifflett P, Sokolow LZ, Ferber JR,
Kurosky S, et al. Effectiveness of seasonal trivalent influenza vaccine for
preventing influenza virus illness among pregnant women: a population-based
case-control study during the 2010-2011 and 2011-2012 influenza seasons. Clin
Infect Dis. 2014 Feb;58(4):449-57.
Sugaya N, Nerome K, Ishida M, Matsumoto M, Mitamura K,
Nirasawa M. Efficacy of inactivated vaccine in preventing antigenically
drifted influenza type A and well-matched type B. JAMA. 1994 Oct
12;272(14):1122-6.
Smits AJ, Hak E, Stalman WA, van Essen GA, Hoes AW, Verheij
TJ. Clinical effectiveness of conventional influenza vaccination in asthmatic
children. Epidemiol Infect. 2002 Apr;128(2):205-11.
Kramarz P, Destefano F, Gargiullo PM, Chen RT, Lieu TA, Davis
RL, et al. Does influenza vaccination prevent asthma exacerbations in
children? J Pediatr. 2001 Mar;138(3):306-10.
Ong BA, Forester J, Fallot A. Does influenza vaccination
improve pediatric asthma outcomes? The Journal of asthma : official journal of
the Association for the Care of Asthma. 2009 Jun;46(5):477-80.
Bueving HJ, Bernsen RM, de Jongste JC, van Suijlekom-Smit LW,
Rimmelzwaan GF, Osterhaus AD, et al. Influenza vaccination in children with
asthma: randomized double-blind placebo-controlled trial. Am J Respir Crit
Care Med. 2004 Feb 15;169(4):488-93.
Christy C, Aligne CA, Auinger P, Pulcino T, Weitzman M.
Effectiveness of influenza vaccine for the prevention of asthma exacerbations.
Arch Dis Child. 2004 Aug;89(8):734-5.
Park CL, Frank AL, Sullivan M, Jindal P, Baxter BD. Influenza
vaccination of children during acute asthma exacerbation and concurrent
prednisone therapy. Pediatrics. 1996 Aug;98(2 Pt 1):196-200.
Herrera GA, Iwane MK, Cortese M, Brown C, Gershman K, Shupe A,
et al. Influenza vaccine effectiveness among 50-64-year-old persons during a
season of poor antigenic match between vaccine and circulating influenza virus
strains: Colorado, United States, 2003-2004. Vaccine. 2007 Jan
02;25(1):154-60.
Hak E, Buskens E, van Essen GA, de Bakker DH, Grobbee DE,
Tacken MA, et al. Clinical effectiveness of influenza vaccination in persons
younger than 65 years with high-risk medical conditions: the PRISMA study.
Arch Intern Med. 2005 Feb 14;165(3):274-80.
Looijmans-Van den Akker I, Verheij TJ, Buskens E, Nichol KL,
Rutten GE, Hak E. Clinical effectiveness of first and repeat influenza
vaccination in adult and elderly diabetic patients. Diabetes Care. 2006
Aug;29(8):1771-6.
Wongsurakiat P, Maranetra KN, Wasi C, Kositanont U,
Dejsomritrutai W, Charoenratanakul S. Acute respiratory illness in patients
with COPD and the effectiveness of influenza vaccination: a randomized
controlled study. Chest. 2004 Jun;125(6):2011-20.
Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine
for patients with chronic obstructive pulmonary disease. Cochrane Database
Syst Rev. 2006 Jan 25(1):CD002733.
Cates CJ, Rowe BH. Vaccines for preventing influenza in people
with asthma. Cochrane Database Syst Rev. 2013 Feb 28(2):CD000364.
Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P,
Vallance P. Risk of myocardial infarction and stroke after acute infection or
vaccination. N Engl J Med. 2004 Dec 16;351(25):2611-8.
Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza
vaccine pilot study in acute coronary syndromes and planned percutaneous
coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS)
Study. Circulation. 2002 May 07;105(18):2143-7.
Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu
vaccination in acute coronary syndromes and planned percutaneous coronary
interventions (FLUVACS) Study. Eur Heart J. 2004 Jan;25(1):25-31.
Ciszewski A, Bilinska ZT, Brydak LB, Kepka C, Kruk M,
Romanowska M, et al. Influenza vaccination in secondary prevention from
coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart
J. 2008 Jun;29(11):1350-8.
Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R,
Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular
events in patients with acute coronary syndrome. Eur Heart J. 2011
Jul;32(14):1730-5.
Breteler JK, Tam JS, Jit M, Ket JC, De Boer MR. Efficacy and
effectiveness of seasonal and pandemic A (H1N1) 2009 influenza vaccines in low
and middle income countries: a systematic review and meta-analysis. Vaccine.
2013 Oct 25;31(45):5168-77.
Asghar Z, Coupland C, Siriwardena N. Influenza vaccination and
risk of stroke: Self-controlled case-series study. Vaccine. 2015 Oct
05;33(41):5458-63.
Black S, Nicolay U, Del Giudice G, Rappuoli R. Influence of
Statins on Influenza Vaccine Response in Elderly Individuals. J Infect Dis.
2016 Apr 15;213(8):1224-8.
Omer SB, Phadke VK, Bednarczyk RA, Chamberlain AT, Brosseau
JL, Orenstein WA. Impact of Statins on Influenza Vaccine Effectiveness Against
Medically Attended Acute Respiratory Illness. J Infect Dis. 2016 Apr
15;213(8):1216-23.
McLean HQ, Chow BD, VanWormer JJ, King JP, Belongia EA. Effect
of Statin Use on Influenza Vaccine Effectiveness. J Infect Dis. 2016 Oct
15;214(8):1150-8.
Song JY, Cheong HJ, Ha SH, Hwang IS, Kee SY, Jeong HW, et al.
Clinical impact of influenza immunization in patients with liver cirrhosis. J
Clin Virol. 2007 Jul;39(3):159-63.
Su FH, Huang YL, Sung FC, Su CT, Hsu WH, Chang SN, et al.
Annual influenza vaccination reduces total hospitalization in patients with
chronic hepatitis B virus infection: A population-based analysis. Vaccine.
2016 Jan 02;34(1):120-7.
Sperling RS, Engel SM, Wallenstein S, Kraus TA, Garrido J,
Singh T, et al. Immunogenicity of trivalent inactivated influenza vaccination
received during pregnancy or postpartum. Obstet Gynecol. 2012
Mar;119(3):631-9.
Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG,
Sammon AB, et al. Obesity is associated with impaired immune response to
influenza vaccination in humans. Int J Obes (Lond). 2012
Aug;36(8):1072-7.
Talbot HK, Coleman LA, Crimin K, Zhu Y, Rock MT, Meece J, et
al. Association between obesity and vulnerability and serologic response to
influenza vaccination in older adults. Vaccine. 2012 Jun
06;30(26):3937-43.
Esposito S, Giavoli C, Trombetta C, Bianchini S, Montinaro V,
Spada A, et al. Immunogenicity, safety and tolerability of inactivated
trivalent influenza vaccine in overweight and obese children. Vaccine. 2016
Jan 02;34(1):56-60.
Gefenaite G, Rahamat-Langendoen J, Ambrozaitis A, Mickiene A,
Jancoriene L, Kuliese M, et al. Seasonal influenza vaccine effectiveness
against influenza in 2012-2013: a hospital-based case-control study in
Lithuania. Vaccine. 2014 Feb 07;32(7):857-63.
Chadwick EG, Chang G, Decker MD, Yogev R, Dimichele D, Edwards
KM. Serologic response to standard inactivated influenza vaccine in human
immunodeficiency virus-infected children. Pediatr Infect Dis J. 1994
Mar;13(3):206-11.
Huang KL, Ruben FL, Rinaldo CR, Jr., Kingsley L, Lyter DW, Ho
M. Antibody responses after influenza and pneumococcal immunization in
HIV-infected homosexual men. JAMA. 1987 Apr 17;257(15):2047-50.
Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P,
Grant RM, et al. Activation of virus replication after vaccination of
HIV-1-infected individuals. J Exp Med. 1995 Dec 1;182(6):1727-37.
Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth
R. Antibody response after influenza vaccination in HIV-infected individuals:
a consecutive 3-year study. Vaccine. 2000 Jul 01;18(26):3040-9.
Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick
J, Clements ML. The influence of HIV infection on antibody responses to a
two-dose regimen of influenza vaccine. JAMA. 1989 Aug 11;262(6):779-83.
Fine AD, Bridges CB, De Guzman AM, Glover L, Zeller B, Wong
SJ, et al. Influenza A among patients with human immunodeficiency virus: an
outbreak of infection at a residential facility in New York City. Clin Infect
Dis. 2001 Jun 15;32(12):1784-91.
Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D,
et al. Trivalent inactivated influenza vaccine in African adults infected with
human immunodeficient virus: double blind, randomized clinical trial of
efficacy, immunogenicity, and safety. Clin Infect Dis. 2011 Jan
01;52(1):128-37.
Madhi SA, Dittmer S, Kuwanda L, Venter M, Cassim H, Lazarus E,
et al. Efficacy and immunogenicity of influenza vaccine in HIV-infected
children: a randomized, double-blind, placebo controlled trial. AIDS. 2013 Jan
28;27(3):369-79.
McKittrick N, Frank I, Jacobson JM, White CJ, Kim D, Kappes R,
et al. Improved immunogenicity with high-dose seasonal influenza vaccine in
HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern
Med. 2013 Jan 01;158(1):19-26.
Hakim H, Allison KJ, Van de Velde LA, Tang L, Sun Y, Flynn PM,
et al. Immunogenicity and safety of high-dose trivalent inactivated influenza
vaccine compared to standard-dose vaccine in children and young adults with
cancer or HIV infection. Vaccine. 2016 Jun 08;34(27):3141-8.
Kumar D, Blumberg EA, Danziger-Isakov L, Kotton CN, Halasa NB,
Ison MG, et al. Influenza vaccination in the organ transplant recipient:
review and summary recommendations. American journal of transplantation :
official journal of the American Society of Transplantation and the American
Society of Transplant Surgeons. 2011 Oct;11(10):2020-30.
Birdwell KA, Ikizler MR, Sannella EC, Wang L, Byrne DW,
Ikizler TA, et al. Decreased antibody response to influenza vaccination in
kidney transplant recipients: a prospective cohort study. Am J Kidney Dis.
2009 Jul;54(1):112-21.
Scharpe J, Evenepoel P, Maes B, Bammens B, Claes K, Osterhaus
AD, et al. Influenza vaccination is efficacious and safe in renal transplant
recipients. American journal of transplantation : official journal of the
American Society of Transplantation and the American Society of Transplant
Surgeons. 2008 Feb;8(2):332-7.
Edvardsson VO, Flynn JT, Deforest A, Kaiser BA, Schulman SL,
Bradley A, et al. Effective immunization against influenza in pediatric renal
transplant recipients. Clin Transplant. 1996 Dec;10(6 Pt 1):556-60.
Nailescu C, Xu X, Zhou H, Hall H, Wilson AC, Leiser JD, et al.
Influenza vaccine after pediatric kidney transplant: a Midwest Pediatric
Nephrology Consortium study. Pediatr Nephrol. 2011 Mar;26(3):459-67.
Krairittichai U, Chittaganpitch M. Efficacy of the trivalent
influenza vaccination in Thai patients with hemodialysis or kidney transplant
compared with healthy volunteers. J Med Assoc Thai. 2013 Mar;96 Suppl
3:S1-7.
Hurst FP, Lee JJ, Jindal RM, Agodoa LY, Abbott KC. Outcomes
associated with influenza vaccination in the first year after kidney
transplantation. Clin J Am Soc Nephrol. 2011 May;6(5):1192-7.
Duchini A, Hendry RM, Nyberg LM, Viernes ME, Pockros PJ.
Immune response to influenza vaccine in adult liver transplant recipients.
Liver transplantation : official publication of the American Association for
the Study of Liver Diseases and the International Liver Transplantation
Society. 2001 Apr;7(4):311-3.
Lawal A, Basler C, Branch A, Gutierrez J, Schwartz M, Schiano
TD. Influenza vaccination in orthotopic liver transplant recipients: absence
of post administration ALT elevation. American journal of transplantation :
official journal of the American Society of Transplantation and the American
Society of Transplant Surgeons. 2004 Nov;4(11):1805-9.
Cordero E, Roca-Oporto C, Bulnes-Ramos A, Aydillo T, Gavalda
J, Moreno A, et al. Two Doses of Inactivated Influenza Vaccine Improve Immune
Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a
Randomized Controlled Clinical Trial. Clin Infect Dis. 2017 Apr
01;64(7):829-38.
Flublok Quadrivalent [Package Insert]. Meriden, CT: Protein
Sciences; 2017.
Flublok [Pachage insert]. Meriden, CT: Protein Sciences;
2017.
Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL,
et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin
influenza vaccine: a randomized controlled trial. JAMA. 2007 Apr
11;297(14):1577-82.
Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger
R, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein
vaccine (FluBlok(R)) against influenza in healthy adults: a randomized,
placebo-controlled trial. Vaccine. 2011 Oct 13;29(44):7733-9.
Keitel WA, Treanor JJ, El Sahly HM, Gilbert A, Meyer AL,
Patriarca PA, et al. Comparative immunogenicity of recombinant influenza
hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons >
or =65 years old. Vaccine. 2009 Dec 11;28(2):379-85.
Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox
MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R)
trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine
administered intramuscularly to healthy adults 50-64 years of age. Vaccine.
2011 Mar 09;29(12):2272-8.
Summary Basis for Regulatory Action–Flublok Quadrivalent. U.S.
Department of Health and Human Services, Food and Drug Administration;
2016.
Dunkle LM, Izikson R, Patriarca P, Goldenthal KL, Muse D,
Callahan J, et al. Efficacy of Recombinant Influenza Vaccine in Adults 50
Years of Age or Older. N Engl J Med. 2017 Jun 22;376(25):2427-36.
King JC, Jr., Cox MM, Reisinger K, Hedrick J, Graham I,
Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of
FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza
vaccine administered intramuscularly to healthy children aged 6-59 months.
Vaccine. 2009 Nov 05;27(47):6589-94.
Fluzone High-Dose [Package Insert]. Swiftwater, PA: Sanofi
Pasteur; 2017.
Couch RB, Winokur P, Brady R, Belshe R, Chen WH, Cate TR, et
al. Safety and immunogenicity of a high dosage trivalent influenza vaccine
among elderly subjects. Vaccine. 2007 Nov 01;25(44):7656-63.
Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ.
Randomized, double-blind controlled phase 3 trial comparing the immunogenicity
of high-dose and standard-dose influenza vaccine in adults 65 years of age and
older. J Infect Dis. 2009 Jul 15;200(2):172-80.
Keitel WA, Atmar RL, Cate TR, Petersen NJ, Greenberg SB, Ruben
F, et al. Safety of high doses of influenza vaccine and effect on antibody
responses in elderly persons. Arch Intern Med. 2006 May
22;166(10):1121-7.
Summary Basis for Regulatory Action, December 23, 2009–Fluzone
High-Dose. U.S. Department of Health and Human Services, Food and Drug
Administration; 2009.
DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J,
Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine
in older adults. N Engl J Med. 2014 Aug 14;371(7):635-45.
DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning
AJ, Greenberg DP. Prevention of serious events in adults 65 years of age or
older: A comparison between high-dose and standard-dose inactivated influenza
vaccines. Vaccine. 2015 Sep 11;33(38):4988-93.
Chit A, Becker DL, DiazGranados CA, Maschio M, Yau E, Drummond
M. Cost-effectiveness of high-dose versus standard-dose inactivated influenza
vaccine in adults aged 65 years and older: an economic evaluation of data from
a randomised controlled trial. Lancet Infect Dis. 2015
Dec;15(12):1459-66.
Gravenstein S, Davidson HE, Taljaard M, Ogarek J, Gozalo P,
Han L, et al. Comparative effectiveness of high-dose versus standard-dose
influenza vaccination on numbers of US nursing home residents admitted to
hospital: a cluster-randomised trial. Lancet Respir Med. 2017 Jul 20.
Richardson DM, Medvedeva EL, Roberts CB, Linkin DR, Centers
for Disease C, Prevention Epicenter P. Comparative effectiveness of high-dose
versus standard-dose influenza vaccination in community-dwelling veterans.
Clin Infect Dis. 2015 Jul 15;61(2):171-6.
Izurieta HS, Thadani N, Shay DK, Lu Y, Maurer A, Foppa IM, et
al. Comparative effectiveness of high-dose versus standard-dose influenza
vaccines in US residents aged 65 years and older from 2012 to 2013 using
Medicare data: a retrospective cohort analysis. Lancet Infect Dis. 2015
Mar;15(3):293-300.
Shay DK, Chillarige Y, Kelman J, Forshee RA, Foppa IM,
Wernecke M, et al. Comparative Effectiveness of High-Dose Versus Standard-Dose
Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza
Deaths During 2012-2013 and 2013-2014. J Infect Dis. 2017 Mar 02.
Summary Basis for Regulatory Action–Fluad. U.S. Department of
Health and Human Services, Food and Drug Administration; 2017.
Fluad [Package Insert]. Holly Springs, NC: Seqirus; 2017.
Van Buynder PG, Konrad S, Van Buynder JL, Brodkin E, Krajden
M, Ramler G, et al. The comparative effectiveness of adjuvanted and
unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly.
Vaccine. 2013 Dec 09;31(51):6122-8.
Mannino S, Villa M, Apolone G, Weiss NS, Groth N, Aquino I, et
al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in
northern Italy. Am J Epidemiol. 2012 Sep 15;176(6):527-33.
Spadea A, Unim B, Colamesta V, Meneghini A, D’Amici AM,
Giudiceandrea B, et al. Is the adjuvanted influenza vaccine more effective
than the trivalent inactivated vaccine in the elderly population? Results of a
case-control study. Vaccine. 2014 Sep 15;32(41):5290-4.
Lee MS, Mahmood K, Adhikary L, August MJ, Cordova J, Cho I, et
al. Measuring antibody responses to a live attenuated influenza vaccine in
children. Pediatr Infect Dis J. 2004 Sep;23(9):852-6.
Nolan T, Lee MS, Cordova JM, Cho I, Walker RE, August MJ, et
al. Safety and immunogenicity of a live-attenuated influenza vaccine blended
and filled at two manufacturing facilities. Vaccine. 2003 Mar
7;21(11-12):1224-31.
Zangwill KM, Droge J, Mendelman P, Marcy SM, Partridge S, Chiu
CY, et al. Prospective, randomized, placebo-controlled evaluation of the
safety and immunogenicity of three lots of intranasal trivalent influenza
vaccine among young children. Pediatr Infect Dis J. 2001 Aug;20(8):740-6.
Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi
T, et al. Immunogenicity and safety of a quadrivalent live attenuated
influenza vaccine in children. Pediatr Infect Dis J. 2012
Jul;31(7):745-51.
Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J. A
randomized, double-blind noninferiority study of quadrivalent live attenuated
influenza vaccine in adults. Vaccine. 2011 Nov 21;29(50):9391-7.
Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra
P, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal
influenzavirus vaccine in children. N Engl J Med. 1998 May
14;338(20):1405-12.
Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block
SL, et al. Efficacy of vaccination with live attenuated, cold-adapted,
trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not
contained in the vaccine. J Pediatr. 2000 Feb;136(2):168-75.
Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A,
Palladino G, et al. Efficacy and safety of 1 and 2 doses of live attenuated
influenza vaccine in vaccine-naive children. Pediatr Infect Dis J. 2009
May;28(5):365-71.
Vesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi
S, Rappaport R, et al. Safety, efficacy, and effectiveness of cold-adapted
influenza vaccine-trivalent against community-acquired, culture-confirmed
influenza in young children attending day care. Pediatrics. 2006
Dec;118(6):2298-312.
Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z,
Huang LM, et al. Efficacy and safety of a live attenuated, cold-adapted
influenza vaccine, trivalent against culture-confirmed influenza in young
children in Asia. Pediatr Infect Dis J. 2007 Jul;26(7):619-28.
Gaglani MJ, Piedra PA, Herschler GB, Griffith ME, Kozinetz CA,
Riggs MW, et al. Direct and total effectiveness of the intranasal,
live-attenuated, trivalent cold-adapted influenza virus vaccine against the
2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr
Adolesc Med. 2004 Jan;158(1):65-73.
Block SL, Heikkinen T, Toback SL, Zheng W, Ambrose CS. The
efficacy of live attenuated influenza vaccine against influenza-associated
acute otitis media in children. Pediatr Infect Dis J. 2011
Mar;30(3):203-7.
Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ,
Belshe RB, et al. Effectiveness of live, attenuated intranasal influenza virus
vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999
Jul 14;282(2):137-44.
Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E,
et al. Comparative efficacy of inactivated and live attenuated influenza
vaccines. N Engl J Med. 2009 Sep 24;361(13):1260-7.
Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum
LL, et al. Prevention of antigenically drifted influenza by inactivated and
live attenuated vaccines. N Engl J Med. 2006 Dec 14;355(24):2513-22.
Ohmit SE, Victor JC, Teich ER, Truscon RK, Rotthoff JR, Newton
DW, et al. Prevention of symptomatic seasonal influenza in 2005-2006 by
inactivated and live attenuated vaccines. J Infect Dis. 2008 Aug
1;198(3):312-7.
Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of
trivalent live attenuated and inactivated influenza vaccines in children and
adults. Influenza and other respiratory viruses. 2011 Mar;5(2):67-75.
Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio
D, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated
(TIV) influenza vaccines in prevention of virus infection and illness
following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and
B viruses. Vaccine. 1999 Dec 10;18(9-10):899-906.
Wang Z, Tobler S, Roayaei J, Eick A. Live attenuated or
inactivated influenza vaccines and medical encounters for respiratory
illnesses among US military personnel. JAMA. 2009 Mar 4;301(9):945-53.
Eick AA, Wang Z, Hughes H, Ford SM, Tobler SK. Comparison of
the trivalent live attenuated vs. inactivated influenza vaccines among U.S.
military service members. Vaccine. 2009 Jun 2;27(27):3568-75.
Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith DD,
Klemola T, et al. Superior relative efficacy of live attenuated influenza
vaccine compared with inactivated influenza vaccine in young children with
recurrent respiratory tract infections. Pediatr Infect Dis J. 2006
Oct;25(10):870-9.
Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE,
Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in
infants and young children. N Engl J Med. 2007 Feb 15;356(7):685-96.
Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y,
Langussis A, et al. Comparison of the efficacy and safety of live attenuated
cold-adapted influenza vaccine, trivalent, with trivalent inactivated
influenza virus vaccine in children and adolescents with asthma. Pediatr
Infect Dis J. 2006 Oct;25(10):860-9.
Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C,
Harvey D, et al. Trivalent live attenuated intranasal influenza vaccine
administered during the 2003-2004 influenza type A (H3N2) outbreak provided
immediate, direct, and indirect protection in children. Pediatrics. 2007
Sep;120(3):e553-64.
Grohskopf LA, Olsen SJ, Sokolow LZ, Bresee JS, Cox NJ, Broder
KR, et al. Prevention and control of seasonal influenza with vaccines:
recommendations of the Advisory Committee on Immunization Practices (ACIP) —
United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Aug
15;63(32):691-7.
CDC. Advisory Committee on Immunization Practices (ACIP).
Summary report: October 29–30, 2014 (Meeting minutes). Atlanta, GA: U.S.
Department of Health and Human Services, Centers for Disease Control and
Prevention; 2014.
Gaglani M, Pruszynski J, Murthy K, Clipper L, Robertson A,
Reis M, et al. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza
A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States.
J Infect Dis. 2016 May 15;213(10):1546-56.
Caspard H, Gaglani M, Clipper L, Belongia EA, McLean HQ,
Griffin MR, et al. Effectiveness of live attenuated influenza vaccine and
inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in
the United States. Vaccine. 2016 Jan 02;34(1):77-82.
Chung JR, Flannery B, Thompson MG, Gaglani M, Jackson ML,
Monto AS, et al. Seasonal Effectiveness of Live Attenuated and Inactivated
Influenza Vaccine. Pediatrics. 2016 Feb;137(2):1-10.
Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA,
Petrie JG, et al. 2014-2015 Influenza Vaccine Effectiveness in the United
States by Vaccine Type. Clin Infect Dis. 2016 Dec 15;63(12):1564-73.
McLean HQ, Caspard H, Griffin MR, Poehling KA, Gaglani M,
Belongia EA, et al. Effectiveness of live attenuated influenza vaccine and
inactivated influenza vaccine in children during the 2014-2015 season.
Vaccine. 2017 May 09;35(20):2685-93.
Advisory Committee on Immunization Practices summary report:
February 26, 2015 (Meeting minutes). . Atlanta, GA: US Department of Health
and Human Services, CDC; 2015.
Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR,
Karron RA. Prevention and Control of Influenza with Vaccines: Recommendations
of the Advisory Committee on Immunization Practices, United States, 2015-16
Influenza Season. MMWR Morb Mortal Wkly Rep. 2015 Aug 7;64(30):818-25.
Cotter CR, Jin H, Chen Z. A single amino acid in the stalk
region of the H1N1pdm influenza virus HA protein affects viral fusion,
stability and infectivity. PLoS Pathog. 2014 Jan;10(1):e1003831.
Caspard H, Coelingh KL, Mallory RM, Ambrose CS. Association of
vaccine handling conditions with effectiveness of live attenuated influenza
vaccine against H1N1pdm09 viruses in the United States. Vaccine. 2016 Sep
30;34(42):5066-72.
FluMist Quadrivalent [Package Insert]. Gaithersburg, MD:
MedImmune; 2016.
Advisory Committee on Immunization Practices (ACIP). Summary
report: June 22–23, 2016 (Meeting Minutes). Atlanta, GA: U.S. Department of
Health and Human Services, Centers for Disease Control and Prevention;
2016.
Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA,
Jernigan DB, et al. Prevention and Control of Seasonal Influenza with
Vaccines. MMWR Recomm Rep. 2016 Aug 26;65(5):1-54.
Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell
S, et al. Effectiveness of seasonal influenza vaccine for adults and children
in preventing laboratory-confirmed influenza in primary care in the United
Kingdom: 2015/16 end-of-season results. Euro Surveill. 2016 Sep
22;21(38).
Nohynek H, Baum U, Syrjanen R, Ikonen N, Sundman J, Jokinen J.
Effectiveness of the live attenuated and the inactivated influenza vaccine in
two-year-olds – a nationwide cohort study Finland, influenza season 2015/16.
Euro Surveill. 2016 Sep 22;21(38).
National Advisory Committee on Immunization. Advisory Commitee
Statement. Canadian Immunization Guide Chapter on Influenza and Statement on
Seasonal Influenza Vaccine for 2016-2017. Addensum: LAIV Use Children and
Adolescents. . Public Health Agency of Canada; 2016.
Ambrose CS, Bright H, Mallory R. Letter to the editor:
Potential causes of the decreased effectiveness of the influenza A(H1N1)pdm09
strain in live attenuated influenza vaccines. Euro Surveill. 2016 Nov
10;21(45).
Ochiai H, Shibata M, Kamimura K, Niwayama S. Evaluation of the
efficacy of split-product trivalent A(H1N1), A(H3N2), and B influenza
vaccines: reactogenicity, immunogenicity and persistence of antibodies
following two doses of vaccines. Microbiology and immunology.
1986;30(11):1141-9.
Kunzel W, Glathe H, Engelmann H, Van Hoecke C. Kinetics of
humoral antibody response to trivalent inactivated split influenza vaccine in
subjects previously vaccinated or vaccinated for the first time. Vaccine. 1996
Aug;14(12):1108-10.
Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, et al.
Long-term immunogenicity of influenza vaccine among the elderly: Risk factors
for poor immune response and persistence. Vaccine. 2010 May
21;28(23):3929-35.
Petrie JG, Ohmit SE, Johnson E, Truscon R, Monto AS.
Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase
Following One or Two Years of Influenza Vaccination. J Infect Dis. 2015 Dec
15;212(12):1914-22.
Skowronski DM, Tweed SA, De Serres G. Rapid decline of
influenza vaccine-induced antibody in the elderly: is it real, or is it
relevant? J Infect Dis. 2008 Feb 15;197(4):490-502.
Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J,
VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in
children and older adults during a single season. Vaccine. 2015 Jan
1;33(1):246-51.
Castilla J, Martinez-Baz I, Martinez-Artola V, Reina G, Pozo
F, Garcia Cenoz M, et al. Decline in influenza vaccine effectiveness with time
after vaccination, Navarre, Spain, season 2011/12. Euro Surveill.
2013;18(5).
Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM,
Nunes B, et al. Low and decreasing vaccine effectiveness against influenza
A(H3) in 2011/12 among vaccination target groups in Europe: results from the
I-MOVE multicentre case-control study. Euro Surveill. 2013;18(5).
Pebody R, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson
CI, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza
vaccine in preventing laboratory-confirmed influenza in primary care in the
United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill.
2013;18(5).
Ferdinands JM, Fry AM, Reynolds S, Petrie J, Flannery B,
Jackson ML, et al. Intraseason waning of influenza vaccine protection:
Evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through
2014-15. Clin Infect Dis. 2016 Dec 29.
Hoskins TW, Davies JR, Allchin A, Miller CL, Pollock TM.
Controlled trial of inactivated influenza vaccine containing the a-Hong Kong
strain during an outbreak of influenza due to the a-England-42-72 strain.
Lancet. 1973 Jul 21;2(7821):116-20.
Hoskins TW, Davies JR, Smith AJ, Allchin A, Miller CL, Pollock
TM. Influenza at Christ’s Hospital: March, 1974. Lancet. 1976 Jan
17;1(7951):105-8.
Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A.
Assessment of inactivated influenza-A vaccine after three outbreaks of
influenza A at Christ’s Hospital. Lancet. 1979 Jan 06;1(8106):33-5.
Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram
ME, De Serres G. Repeated annual influenza vaccination and vaccine
effectiveness: Review of evidence. Expert review of vaccines. 2017 May
31.
Keitel WA, Cate TR, Couch RB, Huggins LL, Hess KR. Efficacy of
repeated annual immunization with inactivated influenza virus vaccines over a
five year period. Vaccine. 1997 Jul;15(10):1114-22.
Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay
DK, et al. Influenza vaccine effectiveness in the community and the household.
Clin Infect Dis. 2013 May;56(10):1363-9.
Ohmit SE, Petrie JG, Malosh RE, Johnson E, Truscon R, Aaron B,
et al. Substantial Influenza Vaccine Effectiveness in Households With Children
During the 2013-2014 Influenza Season, When 2009 Pandemic Influenza A(H1N1)
Virus Predominated. J Infect Dis. 2016 Apr 15;213(8):1229-36.
Cheng AC, Macartney KK, Waterer GW, Kotsimbos T, Kelly PM,
Blyth CC, et al. Repeated vaccination does not appear to impact on influenza
vaccine effectiveness against hospitalisation with confirmed influenza. Clin
Infect Dis. 2017 Mar 17.
McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL,
Friedrich TC, et al. Impact of repeated vaccination on vaccine effectiveness
against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis. 2014 Nov
15;59(10):1375-85.
Martinez-Baz I, Casado I, Navascues A, Diaz-Gonzalez J,
Aguinaga A, Barrado L, et al. Effect of Repeated Vaccination With the Same
Vaccine Component Against 2009 Pandemic Influenza A(H1N1) Virus. J Infect Dis.
2017 Mar 15;215(6):847-55.
France EK, Glanz JM, Xu S, Davis RL, Black SB, Shinefield HR,
et al. Safety of the trivalent inactivated influenza vaccine among children: a
population-based study. Arch Pediatr Adolesc Med. 2004
Nov;158(11):1031-6.
Hambidge SJ, Glanz JM, France EK, McClure D, Xu S, Yamasaki K,
et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23
months old. JAMA. 2006 Oct 25;296(16):1990-7.
Glanz JM, Newcomer SR, Hambidge SJ, Daley MF, Narwaney KJ, Xu
S, et al. Safety of trivalent inactivated influenza vaccine in children aged
24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med. 2011
Aug;165(8):749-55.
Barry DW, Mayner RE, Hochstein HD, Dunlap RC, Rastogi SC,
Hannah JE, et al. Comparative trial of influenza vaccines. II. Adverse
reactions in children and adults. Am J Epidemiol. 1976 Jul;104(1):47-59.
Stockwell MS, Broder KR, Lewis P, Jakob K, Iqbal S, Fernandez
N, et al. Assessing Fever Frequency After Pediatric Live Attenuated Versus
Inactivated Influenza Vaccination. J Pediatric Infect Dis Soc. 2016 Jun
14.
American Academy of Pediatrics. Febrile seizures: clinical
practice guideline for the long-term management of the child with simple
febrile seizures. Pediatrics. 2008;121(6):1281-6.
Francis JR, Richmond P, Robins C, Lindsay K, Levy A, Effler
PV, et al. An observational study of febrile seizures: the importance of viral
infection and immunization. BMC Pediatr. 2016 Dec 03;16(1):202.
Greene SK, Kulldorff M, Lewis EM, Li R, Yin R, Weintraub ES,
et al. Near real-time surveillance for influenza vaccine safety:
proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol. 2010
Jan 15;171(2):177-88.
Australian Government Department of Health and
Ageing–Therapeitic Goods Administration. Investigation into febrile reactions
in young children following 2010 seasonal trivalent influenza vaccination.
2010.
CDC. Update: Recommendations of the Advisory Committee on
Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine
(Afluria) in the United States during 2010-11. MMWR Morb Mortal Wkly Rep. 2010
Aug 13;59(31):989-92.
Rockman S, Dyson A, Koernig S, Becher D, Ng M, Morelli AB, et
al. Evaluation of the bioactivity of influenza vaccine strains in vitro
suggests that the introduction of new strains in the 2010 Southern Hemisphere
trivalent influenza vaccine is associated with adverse events. Vaccine. 2014
Jun 24;32(30):3861-8.
Rockman S, Becher D, Dyson A, Koernig S, Morelli AB, Barnden
M, et al. Role of viral RNA and lipid in the adverse events associated with
the 2010 Southern Hemisphere trivalent influenza vaccine. Vaccine. 2014 Jun
24;32(30):3869-76.
Ramakrishna H, Gutsche JT, Patel PA, Evans AS, Weiner M,
Morozowich ST, et al. The Year in Cardiothoracic and Vascular Anesthesia:
Selected Highlights From 2016. J Cardiothorac Vasc Anesth. 2017
Feb;31(1):1-13.
Airey J, Albano FR, Sawlwin DC, Jones AG, Formica N, Matassa
V, et al. Immunogenicity and safety of a quadrivalent inactivated influenza
virus vaccine compared with a comparator quadrivalent inactivated influenza
vaccine in a pediatric population: A phase 3, randomized noninferiority study.
Vaccine. 2017 May 09;35(20):2745-52.
Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D.
Febrile seizures after 2010-2011 influenza vaccine in young children, United
States: a vaccine safety signal from the vaccine adverse event reporting
system. Vaccine. 2012 Mar 2;30(11):2020-3.
Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM. Signal
identification and evaluation for risk of febrile seizures in children
following trivalent inactivated influenza vaccine in the Vaccine Safety
Datalink Project, 2010-2011. Vaccine. 2012 Mar 02;30(11):2024-31.
CDC. Prevention and control of influenza with vaccines:
recommendations of the Advisory Committee on Immunization Practices (ACIP),
2011. MMWR Morb Mortal Wkly Rep. [Practice Guideline]. 2011 Aug
26;60(33):1128-32.
Nuorti JP, Whitney CG. Prevention of pneumococcal disease
among infants and children – use of 13-valent pneumococcal conjugate vaccine
and 23-valent pneumococcal polysaccharide vaccine – recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010 Dec
10;59(RR-11):1-18.
Duffy J, Weintraub E, Hambidge SJ, Jackson LA, Kharbanda EO,
Klein NP, et al. Febrile Seizure Risk After Vaccination in Children 6 to 23
Months. Pediatrics. 2016 Jul;138(1).
Kawai AT, Martin D, Kulldorff M, Li L, Cole DV,
McMahill-Walraven CN, et al. Febrile Seizures After 2010-2011 Trivalent
Inactivated Influenza Vaccine. Pediatrics. 2015 Sep 14.
Stockwell MS, Broder K, LaRussa P, Lewis P, Fernandez N,
Sharma D, et al. Risk of fever after pediatric trivalent inactivated influenza
vaccine and 13-valent pneumococcal conjugate vaccine. JAMA Pediatr. 2014
Mar;168(3):211-9.
Li R, Stewart B, McNeil MM, Duffy J, Nelson J, Kawai AT, et
al. Post licensure surveillance of influenza vaccines in the Vaccine Safety
Datalink in the 2013-2014 and 2014-2015 seasons. Pharmacoepidemiol Drug Saf.
2016 Apr 1.
Yih WK, Kulldorff M, Sandhu SK, Zichittella L, Maro JC, Cole
DV, et al. Prospective influenza vaccine safety surveillance using fresh data
in the Sentinel System. Pharmacoepidemiology and drug safety. 2016
May;25(5):481-92.
Fluzone Quadrivalent [Package Insert]. Swiftwater, PA: Sanofi
Pasteur; 2017.
Fluarix Quadrivalent [Package Insert]. Research Triangle Park,
NC: GlaxoSmithKline; 2017.
Flulaval Quadrivalent [Package Insert]. Quebec City, QC,
Canada: IB Biomedical Corporation of Quebec; 2017.
Afluria Quadivalent [Package insert]. Parkville, Victoria,
Austalia: Seqirus; 2017.
Wang L, Chandrasekaran V, Domachowske JB, Li P, Innis BL, Jain
VK. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine
in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II
Randomized Trial. J Pediatric Infect Dis Soc. 2015 Jul 16.
Haber P, Moro PL, Cano M, Lewis P, Stewart B, Shimabukuro TT.
Post-licensure surveillance of quadrivalent live attenuated influenza vaccine
United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June
2014. Vaccine. 2015 Apr 15;33(16):1987-92.
Wright PF, Sell SH, Thompson J, Karzon DT. Clinical reactions
and serologic response following inactivated monovalent influenza type B
vaccine in young children and infants. J Pediatr. 1976 Jan;88(1):31-5.
Wright PF, Thompson J, Vaughn WK, Folland DS, Sell SH, Karzon
DT. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an
overview of age-related antigenicity and reactogenicity. J Infect Dis. 1977
Dec;136 Suppl:S731-41.
Wright PF, Dolin R, La Montagne JR. From the National
Institute of Allergy and Infectious Diseases of the National Institutes of
Health, the Center for Disease Control, and the Bureau of Biologics of the
Food and Drug Administration. Summary of clinical trials of influenza
vaccines–II. J Infect Dis. 1976 Dec;134(6):633-8.
Gross PA. Reactogenicity and immunogenicity of bivalent
influenza vaccine in one- and two-dose trials in children: a summary. J Infect
Dis. 1977 Dec;136 Suppl:S616-25.
Bernstein DI, Zahradnik JM, DeAngelis CJ, Cherry JD. Clinical
reactions and serologic responses after vaccination with whole-virus or
split-virus influenza vaccines in children aged 6 to 36 months. Pediatrics.
1982 Apr;69(4):404-8.
Groothuis JR, Levin MJ, Rabalais GP, Meiklejohn G, Lauer BA.
Immunization of high-risk infants younger than 18 months of age with
split-product influenza vaccine. Pediatrics. 1991 Jun;87(6):823-8.
Halasa NB, Gerber MA, Berry AA, Anderson EL, Winokur P,
Keyserling H, et al. Safety and Immunogenicity of Full-Dose Trivalent
Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered
to Children 6 Through 35 Months of Age. J Pediatric Infect Dis Soc. 2015
Sep;4(3):214-24.
Jain VK, Domachowske JB, Wang L, Ofori-Anyinam O,
Rodriguez-Weber MA, Leonardi ML, et al. Time to Change Dosing of Inactivated
Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III,
Randomized, Controlled Trial. J Pediatric Infect Dis Soc. 2017 Jan 06.
Govaert TM, Dinant GJ, Aretz K, Masurel N, Sprenger MJ,
Knottnerus JA. Adverse reactions to influenza vaccine in elderly people:
randomised double blind placebo controlled trial. BMJ. 1993 Oct
16;307(6910):988-90.
Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of
adverse reactions to influenza vaccine in the elderly. A randomized,
placebo-controlled trial. JAMA. 1990 Sep 5;264(9):1139-41.
Nichol KL, Margolis KL, Lind A, Murdoch M, McFadden R, Hauge
M, et al. Side effects associated with influenza vaccination in healthy
working adults. A randomized, placebo-controlled trial. Arch Intern Med. 1996
Jul 22;156(14):1546-50.
Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P.
Safety of trivalent inactivated influenza vaccines in adults: background for
pandemic influenza vaccine safety monitoring. Vaccine. 2009 Mar
26;27(15):2114-20.
21 CFR Part 600.80. Postmarketing reporting of adverse
experiences. . Code of Federal Regulations. 2010;Title 21(http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=600/80external icon).
DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M,
Talbot HK. High-dose trivalent influenza vaccine compared to standard dose
vaccine in elderly adults: safety, immunogenicity and relative efficacy during
the 2009-2010 season. Vaccine. 2013 Jan 30;31(6):861-6.
Moro PL, Arana J, Cano M, Menschik D, Yue X, Lewis P, et al.
Postlicensure safety surveillance for high-dose trivalent inactivated
influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July
2010-31 December 2010. Clin Infect Dis. 2012 Jun;54(11):1608-14.
Kaka AS, Filice GA, Myllenbeck S, Nichol KL. Comparison of
Side Effects of the 2015-2016 High-Dose, Inactivated, Trivalent Influenza
Vaccine and Standard Dose, Inactivated, Trivalent Influenza Vaccine in Adults
>/=65 Years. Open Forum Infect Dis. 2017 Winter;4(1):ofx001.
Jain VK, Chandrasekaran V, Wang L, Li P, Liu A, Innis BL. A
historically-controlled Phase III study in adults to characterize the
acceptability of a process change for manufacturing inactivated quadrivalent
influenza vaccine. BMC Infect Dis. 2014;14:133.
Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M.
Post-licensure surveillance of quadrivalent inactivated influenza (IIV4)
vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS),
July 1, 2013-May 31, 2015. Vaccine. 2016 May 11;34(22):2507-12.
Pasteur S. Fluzone Intradermal [Package Insert]. Swiftwater,
PA. 2013.
Young F, Marra F. A systematic review of intradermal influenza
vaccines. Vaccine. 2011 Nov 8;29(48):8788-801.
Moro PL, Harrington T, Shimabukuro T, Cano M, Museru OI,
Menschik D, et al. Adverse events after Fluzone (R) Intradermal vaccine
reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.
Vaccine. 2013 Oct 9;31(43):4984-7.
Moro PL, Winiecki S, Lewis P, Shimabukuro TT, Cano M.
Surveillance of adverse events after the first trivalent inactivated influenza
vaccine produced in mammalian cell culture (Flucelvax((R))) reported to the
Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
Vaccine. 2015 Nov 27;33(48):6684-8.
Daubeney P, Taylor CJ, McGaw J, Brown EM, Ghosal S, Keeton BR,
et al. Immunogenicity and tolerability of a trivalent influenza subunit
vaccine (Influvac) in high-risk children aged 6 months to 4 years. Br J Clin
Pract. 1997 Mar;51(2):87-90.
Berry BB, Ehlert DA, Battiola RJ, Sedmak G. Influenza
vaccination is safe and immunogenic when administered to hospitalized
patients. Vaccine. 2001 May 14;19(25-26):3493-8.
Wongsurakiat P, Maranetra KN, Gulprasutdilog P, Aksornint M,
Srilum W, Ruengjam C, et al. Adverse effects associated with influenza
vaccination in patients with COPD: a randomized controlled study. Respirology.
2004 Nov;9(4):550-6.
Patria MF, Tenconi R, Esposito S. Efficacy and safety of
influenza vaccination in children with asthma. Expert review of vaccines. 2012
Apr;11(4):461-8.
Cates CJ, Rowe BH. Vaccines for preventing influenza in people
with asthma. Cochrane Database Syst Rev. 2013;2:CD000364.
American Lung Association Asthma Clinical Research Centers.
The safety of inactivated influenza vaccine in adults and children with
asthma. N Engl J Med. 2001 Nov 22;345(21):1529-36.
Nicholson KG, Nguyen-Van-Tam JS, Ahmed AH, Wiselka MJ, Leese
J, Ayres J, et al. Randomised placebo-controlled crossover trial on effect of
inactivated influenza vaccine on pulmonary function in asthma. Lancet. 1998
Jan 31;351(9099):326-31.
Kmiecik T, Arnoux S, Kobryn A, Gorski P. Influenza vaccination
in adults with asthma: safety of an inactivated trivalent influenza vaccine.
The Journal of asthma : official journal of the Association for the Care of
Asthma. 2007 Dec;44(10):817-22.
Ho DD. HIV-1 viraemia and influenza. Lancet. 1992 Jun
20;339(8808):1549.
Amendola A, Boschini A, Colzani D, Anselmi G, Oltolina A,
Zucconi R, et al. Influenza vaccination of HIV-1-positive and HIV-1-negative
former intravenous drug users. J Med Virol. 2001 Dec;65(4):644-8.
Fowke KR, D’Amico R, Chernoff DN, Pottage JC, Jr., Benson CA,
Sha BE, et al. Immunologic and virologic evaluation after influenza
vaccination of HIV-1-infected patients. AIDS. 1997 Jul;11(8):1013-21.
Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D.
Influenza vaccination of human immunodeficiency virus (HIV)-infected adults:
impact on plasma levels of HIV type 1 RNA and determinants of antibody
response. Clin Infect Dis. 1999 Mar;28(3):541-7.
Glesby MJ, Hoover DR, Farzadegan H, Margolick JB, Saah AJ. The
effect of influenza vaccination on human immunodeficiency virus type 1 load: a
randomized, double-blind, placebo-controlled study. J Infect Dis. 1996
Dec;174(6):1332-6.
Sullivan PS, Hanson DL, Dworkin MS, Jones JL, Ward JW. Effect
of influenza vaccination on disease progression among HIV-infected persons.
AIDS. 2000 Dec 1;14(17):2781-5.
Couch RB. Influenza, influenza virus vaccine, and human
immunodeficiency virus infection. Clin Infect Dis. 1999 Mar;28(3):548-51.
Gunthard HF, Wong JK, Spina CA, Ignacio C, Kwok S,
Christopherson C, et al. Effect of influenza vaccination on viral replication
and immune response in persons infected with human immunodeficiency virus
receiving potent antiretroviral therapy. J Infect Dis. 2000
Feb;181(2):522-31.
Danziger-Isakov L, Cherkassky L, Siegel H, McManamon M, Kramer
K, Budev M, et al. Effects of influenza immunization on humoral and cellular
alloreactivity in humans. Transplantation. 2010 Apr 15;89(7):838-44.
Fraund S, Wagner D, Pethig K, Drescher J, Girgsdies OE,
Haverich A. Influenza vaccination in heart transplant recipients. J Heart Lung
Transplant. 1999 Mar;18(3):220-5.
Suzuki M, Torii Y, Kawada J, Kimura H, Kamei H, Onishi Y, et
al. Immunogenicity of inactivated seasonal influenza vaccine in adult and
pediatric liver transplant recipients over two seasons. Microbiology and
immunology. 2013 Oct;57(10):715-22.
Moon JS, Souayah N. Guillain-Barre syndrome triggered by
influenza vaccination in a recipient of liver transplant on FK506. Liver
transplantation : official publication of the American Association for the
Study of Liver Diseases and the International Liver Transplantation Society.
2006 Oct;12(10):1537-9.
Raman KS, Chandrasekar T, Reeve RS, Roberts ME, Kalra PA.
Influenza vaccine-induced rhabdomyolysis leading to acute renal transplant
dysfunction. Nephrology, dialysis, transplantation : official publication of
the European Dialysis and Transplant Association – European Renal Association.
2006 Feb;21(2):530-1.
Steinemann TL KB, Jennings CD. Corneal allograft rejection
following immunization. Am J Ophthalmol 1988;106:575-8.
Solomon A F-PJ. Bilateral simultaneous corneal graft rejection
after influenza vaccination. . Am J Ophthalmol. 1996;121:708-9.
Wertheim MS KM, Cook SD, Tole DM. Corneal transplant rejection
following influenza vaccination. . Br J Ophthalmol. 2006;90(925).
Hamilton A, Massera R, Maloof A. Stromal rejection in a deep
anterior lamellar keratoplasty following influenza vaccination. Clin Exp
Ophthalmol. 2015 Dec;43(9):838-9.
Kalra V, Chaudhry R, Dua T, Dhawan B, Sahu JK, Mridula B.
Association of Campylobacter jejuni infection with childhood Guillain-Barre
syndrome: a case-control study. J Child Neurol. 2009 Jun;24(6):664-8.
Jacobs BC, Rothbarth PH, van der Meche FG, Herbrink P, Schmitz
PI, de Klerk MA, et al. The spectrum of antecedent infections in
Guillain-Barre syndrome: a case-control study. Neurology. 1998
Oct;51(4):1110-5.
Sheikh KA, Nachamkin I, Ho TW, Willison HJ, Veitch J, Ung H,
et al. Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome:
molecular mimicry and host susceptibility. Neurology. 1998
Aug;51(2):371-8.
Ropper AH. The Guillain-Barre syndrome. N Engl J Med. 1992 Apr
23;326(17):1130-6.
Sivadon-Tardy V, Orlikowski D, Porcher R, Sharshar T, Durand
MC, Enouf V, et al. Guillain-Barre syndrome and influenza virus infection.
Clin Infect Dis. 2009 Jan 01;48(1):48-56.
Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA,
Ziegler DW, Retailliau HF, et al. Guillain-Barre syndrome following
vaccination in the National Influenza Immunization Program, United States,
1976–1977. Am J Epidemiol. 1979 Aug;110(2):105-23.
Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV,
Weintraub E, et al. Guillain-Barre syndrome following influenza vaccination.
JAMA. 2004 Nov 24;292(20):2478-81.
Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M,
Nash D, et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994
influenza vaccines. N Engl J Med. 1998 Dec 17;339(25):1797-802.
Hurwitz ES, Schonberger LB, Nelson DB, Holman RC.
Guillain-Barre syndrome and the 1978-1979 influenza vaccine. N Engl J Med.
1981 Jun 25;304(26):1557-61.
Kaplan JE, Katona P, Hurwitz ES, Schonberger LB.
Guillain-Barre syndrome in the United States, 1979-1980 and 1980-1981. Lack of
an association with influenza vaccination. JAMA. 1982 Aug
13;248(6):698-700.
Chen R, Kent J, Rhodes P, al. e. Investigations of a possible
association between influenza vaccination and Guillain-Barre syndrome in the
United States, 1990-1991 [Abstract 040]. Post Marketing Surveillance.
1992;6:5-6.
Juurlink DN, Stukel TA, Kwong J, Kopp A, McGeer A, Upshur RE,
et al. Guillain-Barre syndrome after influenza vaccination in adults: a
population-based study. Arch Intern Med. 2006 Nov 13;166(20):2217-21.
Tam CC, O’Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues
LC. Guillain-Barre syndrome and preceding infection with campylobacter,
influenza and Epstein-Barr virus in the general practice research database.
PLoS One. 2007 Apr 04;2(4):e344.
Hughes RA, Charlton J, Latinovic R, Gulliford MC. No
association between immunization and Guillain-Barre syndrome in the United
Kingdom, 1992 to 2000. Arch Intern Med. 2006 Jun 26;166(12):1301-4.
Stowe J, Andrews N, Wise L, Miller E. Investigation of the
temporal association of Guillain-Barre syndrome with influenza vaccine and
influenzalike illness using the United Kingdom General Practice Research
Database. Am J Epidemiol. 2009 Feb 01;169(3):382-8.
Martin Arias LH, Sanz R, Sainz M, Treceno C, Carvajal A.
Guillain-Barre syndrome and influenza vaccines: A meta-analysis. Vaccine. 2015
Jul 17;33(31):3773-8.
Centers for Disease C, Prevention. Safety of influenza A
(H1N1) 2009 monovalent vaccines – United States, October 1-November 24, 2009.
MMWR Morb Mortal Wkly Rep. 2009 Dec 11;58(48):1351-6.
Tokars JI, Lewis P, DeStefano F, Wise M, Viray M, Morgan O, et
al. The risk of Guillain-Barre syndrome associated with influenza A (H1N1)
2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results
from self-controlled analyses. Pharmacoepidemiology and drug safety. 2012
May;21(5):546-52.
Wise ME, Viray M, Sejvar JJ, Lewis P, Baughman AL, Connor W,
et al. Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination
campaign: population-based surveillance among 45 million Americans. Am J
Epidemiol. 2012 Jun 01;175(11):1110-9.
Greene SK, Rett M, Weintraub ES, Li L, Yin R, Amato AA, et al.
Risk of confirmed Guillain-Barre syndrome following receipt of monovalent
inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine
Safety Datalink Project, 2009-2010. Am J Epidemiol. 2012 Jun
01;175(11):1100-9.
Yih WK, Lee GM, Lieu TA, Ball R, Kulldorff M, Rett M, et al.
Surveillance for adverse events following receipt of pandemic 2009 H1N1
vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM)
System, 2009-2010. Am J Epidemiol. 2012 Jun 01;175(11):1120-8.
Burwen DR, Sandhu SK, MaCurdy TE, Kelman JA, Gibbs JM, Garcia
B, et al. Surveillance for Guillain-Barre syndrome after influenza vaccination
among the Medicare population, 2009-2010. Am J Public Health. 2012
Oct;102(10):1921-7.
Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W,
Burwen DR, et al. Association between Guillain-Barre syndrome and influenza A
(H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.
Lancet. 2013 Apr 27;381(9876):1461-8.
Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome,
influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect
Dis. 2014 Apr;58(8):1149-55.
Pritchard J, Mukherjee R, Hughes RA. Risk of relapse of
Guillain-Barre syndrome or chronic inflammatory demyelinating
polyradiculoneuropathy following immunisation. J Neurol Neurosurg Psychiatry.
2002 Sep;73(3):348-9.
Baxter R, Lewis N, Bakshi N, Vellozzi C, Klein NP, Network C.
Recurrent Guillain-Barre syndrome following vaccination. Clin Infect Dis. 2012
Mar;54(6):800-4.
National Advisory Committee on I. An Advisory Committee
Statement (ACS). National Advisory Committee on Immunization (NACI).
Supplementary Statement for the 2001-2002 season: influenza vaccination of
persons who experienced oculo-respiratory syndrome following previous
influenza vaccination. Can Commun Dis Rep. 2001 Nov 15;27:1-7.
National Advisory Committee on I. An Advisory Committee
Statement (ACS). National Advisory Committee on Immunization (NACI).
Supplementary statement on influenza vaccination: continued use of Fluviral
influenza vaccine in the 2000-2001 season. Can Commun Dis Rep. 2001 Jan
15;27:1-3.
Boulianne N, De Serres G, Duval B, Shadmani R, Rochette L.
Clinical manifestations and incidence of oculo-respiratory syndrome following
influenza vaccination–Quebec, 2000. Can Commun Dis Rep. 2001 May
15;27(10):85-90.
De Serres G, Toth E, Menard S, Grenier JL, Roussel R, Tremblay
M, et al. Oculo-respiratory syndrome after influenza vaccination: trends over
four influenza seasons. Vaccine. 2005 May 25;23(28):3726-32.
Skowronski DM, De Serres G, Hebert J, Stark D, Warrington R,
Macnabb J, et al. Skin testing to evaluate oculo-respiratory syndrome (ORS)
associated with influenza vaccination during the 2000-2001 season. Vaccine.
2002 Jun 21;20(21-22):2713-9.
De Serres G, Skowronski DM, Guay M, Rochette L, Jacobsen K,
Fuller T, et al. Recurrence risk of oculorespiratory syndrome after influenza
vaccination: randomized controlled trial of previously affected persons. Arch
Intern Med. 2004 Nov 08;164(20):2266-72.
Skowronski DM, Strauss B, Kendall P, Duval B, De Serres G. Low
risk of recurrence of oculorespiratory syndrome following influenza
revaccination. CMAJ. 2002 Oct 15;167(8):853-8.
Centers for Disease C, Prevention. Summary of the joint
statement on thimerosal in vaccines. American Academy of Family Physicians,
American Academy of Pediatrics, Advisory Committee on Immunization Practices,
Public Health Service. MMWR Morb Mortal Wkly Rep. 2000 Jul 14;49(27):622,
31.
Stratton K, Gable, A., McCormick, M.C. Report of the Institute
of Medicine. Immunization safety review: thimerosal containing vaccines and
neurodevelopmental disorders. In: Stratton K, McCormick, M.C., editor.
Washington, DC: National Academy Press; 2001.
Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury
concentrations and metabolism in infants receiving vaccines containing
thiomersal: a descriptive study. Lancet. 2002 Nov 30;360(9347):1737-41.
Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH,
Black SB, et al. Safety of thimerosal-containing vaccines: a two-phased study
of computerized health maintenance organization databases. Pediatrics. 2003
Nov;112(5):1039-48.
McCormick M, Bayer, R., Berg A,, et al. Report of the
Institute of Medicine. Immunization safety review: vaccines and autism.
Washington, DC: Institute of Medicine; 2004.
Pichichero ME, Gentile A, Giglio N, Umido V, Clarkson T,
Cernichiari E, et al. Mercury levels in newborns and infants after receipt of
thimerosal-containing vaccines. Pediatrics. 2008 Feb;121(2):e208-14.
Schechter R, Grether JK. Continuing increases in autism
reported to California’s developmental services system: mercury in retrograde.
Arch Gen Psychiatry. 2008 Jan;65(1):19-24.
Croen LA, Matevia M, Yoshida CK, Grether JK. Maternal Rh D
status, anti-D immune globulin exposure during pregnancy, and risk of autism
spectrum disorders. Am J Obstet Gynecol. 2008 Sep;199(3):234 e1-6.
Tozzi AE, Bisiacchi P, Tarantino V, De Mei B, D’Elia L,
Chiarotti F, et al. Neuropsychological performance 10 years after immunization
in infancy with thimerosal-containing vaccines. Pediatrics. 2009
Feb;123(2):475-82.
Price CS, Thompson WW, Goodson B, Weintraub ES, Croen LA,
Hinrichsen VL, et al. Prenatal and infant exposure to thimerosal from vaccines
and immunoglobulins and risk of autism. Pediatrics. 2010
Oct;126(4):656-64.
Pichichero ME, Gentile A, Giglio N, Alonso MM, Fernandez
Mentaberri MV, Zareba G, et al. Mercury levels in premature and low birth
weight newborn infants after receipt of thimerosal-containing vaccines. J
Pediatr. 2009 Oct;155(4):495-9.
Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen
VL, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to
10 years. N Engl J Med. 2007 Sep 27;357(13):1281-92.
Barile JP, Kuperminc GP, Weintraub ES, Mink JW, Thompson WW.
Thimerosal exposure in early life and neuropsychological outcomes 7-10 years
later. J Pediatr Psychol. 2012 Jan-Feb;37(1):106-18.
Izikson R, Leffell DJ, Bock SA, Patriarca PA, Post P, Dunkle
LM, et al. Randomized comparison of the safety of Flublok((R)) versus licensed
inactivated influenza vaccine in healthy, medically stable adults >/= 50
years of age. Vaccine. 2015 Nov 27;33(48):6622-8.
Clinical Review, January 16, 2013–Flublok. U.S. Department of
Health and Human Services, Food and Drug Administration; 2013.
Woo EJ. Allergic reactions after egg-free recombinant
influenza vaccine: reports to the US Vaccine Adverse Event Reporting System.
Clin Infect Dis. 2015 Mar 01;60(5):777-80.
Ruggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J,
Friedlander S, et al. Anaphylaxis: case definition and guidelines for data
collection, analysis, and presentation of immunization safety data. Vaccine.
2007 Aug 01;25(31):5675-84.
Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE.
Shedding and immunogenicity of live attenuated influenza vaccine virus in
subjects 5-49 years of age. Vaccine. 2008 Sep 08;26(38):4940-6.
Talbot TR, Crocker DD, Peters J, Doersam JK, Ikizler MR,
Sannella E, et al. Duration of virus shedding after trivalent intranasal live
attenuated influenza vaccination in adults. Infect Control Hosp Epidemiol.
2005 May;26(5):494-500.
Ali T, Scott N, Kallas W, Halliwell ME, Savino C, Rosenberg E,
et al. Detection of influenza antigen with rapid antibody-based tests after
intranasal influenza vaccination (FluMist). Clin Infect Dis. 2004 Mar
01;38(5):760-2.
Mallory RM, Yi T, Ambrose CS. Shedding of Ann Arbor strain
live attenuated influenza vaccine virus in children 6-59 months of age.
Vaccine. 2011 Jun 10;29(26):4322-7.
King JC, Jr., Treanor J, Fast PE, Wolff M, Yan L, Iacuzio D,
et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of
influenza virus vaccine, trivalent, types A and B, live cold-adapted,
administered to human immunodeficiency virus (HIV)-infected and
non-HIV-infected adults. J Infect Dis. 2000 Feb;181(2):725-8.
King JC, Jr., Fast PE, Zangwill KM, Weinberg GA, Wolff M, Yan
L, et al. Safety, vaccine virus shedding and immunogenicity of trivalent,
cold-adapted, live attenuated influenza vaccine administered to human
immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis
J. 2001 Dec;20(12):1124-31.
Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpaa R,
Salmi A, et al. A randomized, double-blind study of the safety,
transmissibility and phenotypic and genotypic stability of cold-adapted
influenza virus vaccine. Pediatr Infect Dis J. 2006 Jul;25(7):590-5.
Cha TA, Kao K, Zhao J, Fast PE, Mendelman PM, Arvin A.
Genotypic stability of cold-adapted influenza virus vaccine in an efficacy
clinical trial. J Clin Microbiol. 2000 Feb;38(2):839-45.
Zhou B, Meliopoulos VA, Wang W, Lin X, Stucker KM, Halpin RA,
et al. Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a
Pathogenic Virus. J Virol. 2016 Oct 01;90(19):8454-63.
Belshe RB, Nichol KL, Black SB, Shinefield H, Cordova J,
Walker R, et al. Safety, efficacy, and effectiveness of live, attenuated,
cold-adapted influenza vaccine in an indicated population aged 5-49 years.
Clin Infect Dis. 2004 Oct 01;39(7):920-7.
Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, et
al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort
of children and adolescents. Pediatr Infect Dis J. 2004 Feb;23(2):138-44.
King JC, Jr., Lagos R, Bernstein DI, Piedra PA, Kotloff K,
Bryant M, et al. Safety and immunogenicity of low and high doses of trivalent
live cold-adapted influenza vaccine administered intranasally as drops or
spray to healthy children. J Infect Dis. 1998 May;177(5):1394-7.
Redding G, Walker RE, Hessel C, Virant FS, Ayars GH, Bensch G,
et al. Safety and tolerability of cold-adapted influenza virus vaccine in
children and adolescents with asthma. Pediatr Infect Dis J. 2002
Jan;21(1):44-8.
Piedra PA, Yan L, Kotloff K, Zangwill K, Bernstein DI, King J,
et al. Safety of the trivalent, cold-adapted influenza vaccine in
preschool-aged children. Pediatrics. 2002 Oct;110(4):662-72.
Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live
attenuated influenza vaccine in children 2-7 years of age. Vaccine. 2008 Sep
12;26 Suppl 4:D10-6.
Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts
M, et al. Live attenuated influenza vaccine, trivalent, is safe in healthy
children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a
community-based, nonrandomized, open-label trial. Pediatrics. 2005
Sep;116(3):e397-407.
Gaglani MJ, Piedra PA, Riggs M, Herschler G, Fewlass C, Glezen
WP. Safety of the intranasal, trivalent, live attenuated influenza vaccine
(LAIV) in children with intermittent wheezing in an open-label field trial.
Pediatr Infect Dis J. 2008 May;27(5):444-52.
Izurieta HS, Haber P, Wise RP, Iskander J, Pratt D, Mink C, et
al. Adverse events reported following live, cold-adapted, intranasal influenza
vaccine. JAMA. 2005 Dec 07;294(21):2720-5.
Haber P, Moro PL, Cano M, Vellozzi C, Lewis P, Woo EJ, et al.
Post-Licensure Surveillance of Trivalent Live-Attenuated Influenza Vaccine in
Children Aged 2-18 Years, Vaccine Adverse Event Reporting System, United
States, July 2005-June 2012. J Pediatric Infect Dis Soc. 2015
Sep;4(3):205-13.
Baxter R, Eaton A, Hansen J, Aukes L, Caspard H, Ambrose CS.
Safety of quadrivalent live attenuated influenza vaccine in subjects aged
2-49years. Vaccine. 2017 Mar 01;35(9):1254-8.
Jackson LA, Holmes SJ, Mendelman PM, Huggins L, Cho I, Rhorer
J. Safety of a trivalent live attenuated intranasal influenza vaccine,
FluMist, administered in addition to parenteral trivalent inactivated
influenza vaccine to seniors with chronic medical conditions. Vaccine. 1999
Apr 09;17(15-16):1905-9.
Curtis D, Ning MF, Armon C, Li S, Weinberg A. Safety,
immunogenicity and shedding of LAIV4 in HIV-infected and uninfected children.
Vaccine. 2015 Sep 11;33(38):4790-7.
Ambrose CS, Dubovsky F, Yi T, Belshe RB, Ashkenazi S. The
safety and efficacy of live attenuated influenza vaccine in young children
with asthma or prior wheezing. Eur J Clin Microbiol Infect Dis. 2012
Oct;31(10):2549-57.
Ray GT, Lewis N, Goddard K, Ross P, Duffy J, DeStefano F, et
al. Asthma exacerbations among asthmatic children receiving live attenuated
versus inactivated influenza vaccines. Vaccine. 2017 May
09;35(20):2668-75.
Duffy J, Lewis M, Harrington T, Baxter R, Belongia EA, Jackson
LA, et al. Live attenuated influenza vaccine use and safety in children and
adults with asthma. Ann Allergy Asthma Immunol. 2017 Apr;118(4):439-44.
Sheffield JS, Greer LG, Rogers VL, Roberts SW, Lytle H,
McIntire DD, et al. Effect of influenza vaccination in the first trimester of
pregnancy. Obstet Gynecol. 2012 Sep;120(3):532-7.
McMillan M, Porritt K, Kralik D, Costi L, Marshall H.
Influenza vaccination during pregnancy: a systematic review of fetal death,
spontaneous abortion, and congenital malformation safety outcomes. Vaccine.
2015 Apr 27;33(18):2108-17.
Munoz FM, Greisinger AJ, Wehmanen OA, Mouzoon ME, Hoyle JC,
Smith FA, et al. Safety of influenza vaccination during pregnancy. Am J Obstet
Gynecol. 2005 Apr;192(4):1098-106.
Moro PL, Broder K, Zheteyeva Y, Walton K, Rohan P, Sutherland
A, et al. Adverse events in pregnant women following administration of
trivalent inactivated influenza vaccine and live attenuated influenza vaccine
in the Vaccine Adverse Event Reporting System, 1990-2009. Am J Obstet Gynecol.
2011 Feb;204(2):146 e1-7.
Moro P, Baumblatt J, Lewis P, Cragan J, Tepper N, Cano M.
Surveillance of Adverse Events After Seasonal Influenza Vaccination in
Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting
System, July 2010-May 2016. Drug Saf. 2017 Feb;40(2):145-52.
Black S, Eskola J, Siegrist CA, Halsey N, Macdonald N, Law B,
et al. Importance of background rates of disease in assessment of vaccine
safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet.
2009 Dec 19;374(9707):2115-22.
Chambers CD, Johnson DL, Xu R, Luo YJ, Louik C, Mitchell AA,
et al. Safety of the 2010-11, 2011-12, 2012-13, and 2013-14 seasonal influenza
vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery,
and small for gestational age infants, a study from the cohort arm of VAMPSS.
Vaccine. 2016 Aug 17;34(37):4443-9.
Irving SA, Kieke BA, Donahue JG, Mascola MA, Baggs J,
DeStefano F, et al. Trivalent inactivated influenza vaccine and spontaneous
abortion. Obstet Gynecol. 2013 Jan;121(1):159-65.
Advisory Committee on Immunization Practices summary report:
June 24–25, 2015 (Meeting minutes). . Atlanta, GA: US Department of Health and
Human Services, CDC; 2015.
Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal
influenza immunization and birth outcomes of stillbirth and spontaneous
abortion: a systematic review and meta-analysis. Clin Infect Dis. 2015 Mar
01;60(5):e11-9.
Mak TK, Mangtani P, Leese J, Watson JM, Pfeifer D. Influenza
vaccination in pregnancy: current evidence and selected national policies.
Lancet Infect Dis. 2008 Jan;8(1):44-52.
Moro PL, Tepper NK, Grohskopf LA, Vellozzi C, Broder K. Safety
of seasonal influenza and influenza A (H1N1) 2009 monovalent vaccines in
pregnancy. Expert review of vaccines. 2012 Aug;11(8):911-21.
Munoz FM. Safety of influenza vaccines in pregnant women. Am J
Obstet Gynecol. 2012 Sep;207(3 Suppl):S33-7.
Polyzos KA, Konstantelias AA, Pitsa CE, Falagas ME. Maternal
Influenza Vaccination and Risk for Congenital Malformations: A Systematic
Review and Meta-analysis. Obstet Gynecol. 2015 Nov;126(5):1075-84.
Louik C, Kerr S, Van Bennekom CM, Chambers C, Jones KL, Schatz
M, et al. Safety of the 2011-12, 2012-13, and 2013-14 seasonal influenza
vaccines in pregnancy: Preterm delivery and specific malformations, a study
from the case-control arm of VAMPSS. Vaccine. 2016 Aug 17;34(37):4450-9.
Omer SB, Goodman D, Steinhoff MC, Rochat R, Klugman KP, Stoll
BJ, et al. Maternal influenza immunization and reduced likelihood of
prematurity and small for gestational age births: a retrospective cohort
study. PLoS Med. 2011 May;8(5):e1000441.
Richards JL, Hansen C, Bredfeldt C, Bednarczyk RA, Steinhoff
MC, Adjaye-Gbewonyo D, et al. Neonatal outcomes after antenatal influenza
immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth,
birth weight, and small for gestational age birth. Clin Infect Dis. 2013
May;56(9):1216-22.
Nordin JD, Kharbanda EO, Vazquez Benitez G, Lipkind H,
Vellozzi C, Destefano F, et al. Maternal influenza vaccine and risks for
preterm or small for gestational age birth. J Pediatr. 2014 May;164(5):1051-7
e2.
Dodds L, Macdonald N, Scott J, Spencer A, Allen VM, McNeil S.
The association between influenza vaccine in pregnancy and adverse neonatal
outcomes. J Obstet Gynaecol Can. 2012 Aug;34(8):714-20.
Fell DB, Sprague AE, Liu N, Yasseen AS, 3rd, Wen SW, Smith G,
et al. H1N1 influenza vaccination during pregnancy and fetal and neonatal
outcomes. Am J Public Health. 2012 Jun;102(6):e33-40.
Zerbo O, Modaressi S, Chan B, Goddard K, Lewis N, Bok K, et
al. No association between influenza vaccination during pregnancy and adverse
birth outcomes. Vaccine. 2017 May 31;35(24):3186-90.
Fell DB, Platt RW, Lanes A, Wilson K, Kaufman JS, Basso O, et
al. Fetal death and preterm birth associated with maternal influenza
vaccination: systematic review. BJOG. 2015 Jan;122(1):17-26.
Vazquez-Benitez G, Kharbanda EO, Naleway AL, Lipkind H,
Sukumaran L, McCarthy NL, et al. Risk of Preterm or Small-for-Gestational-Age
Birth After Influenza Vaccination During Pregnancy: Caveats When Conducting
Retrospective Observational Studies. Am J Epidemiol. 2016 Aug
01;184(3):176-86.
Zerbo O, Qian Y, Yoshida C, Fireman BH, Klein NP, Croen LA.
Association Between Influenza Infection and Vaccination During Pregnancy and
Risk of Autism Spectrum Disorder. JAMA Pediatr. 2017 Jan
02;171(1):e163609.
Toback SL, Beigi R, Tennis P, Sifakis F, Calingaert B, Ambrose
CS. Maternal outcomes among pregnant women receiving live attenuated influenza
vaccine. Influenza Other Respir Viruses. 2012 Jan;6(1):44-51.
Wood RA, Berger M, Dreskin SC, Setse R, Engler RJ, Dekker CL,
et al. An algorithm for treatment of patients with hypersensitivity reactions
after vaccines. Pediatrics. 2008 Sep;122(3):e771-7.
Kroger A.T. DJ, Vázquez M. Best Practices Guidance of the
Advisory Committee on Immunization Practices (ACIP). www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdfpdf icon. Atlanta:
Centers for DIsease Control and Prevention; 2017 [cited 2017 27 April];
Available from: www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdfpdf icon.
McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ,
Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults.
J Allergy Clin Immunol. 2016 Mar;137(3):868-78.
Advisory Committee on Immunization Practices summary report:
June 20–21, 2012 (Meeting minutes). . Atlanta, GA: US Department of Health and
Human Services, CDC; 2012.
Advisory Committee on Immunization Practices summary report:
June 19–20, 2013 (Meeting minutes). Atlanta, GA: US Department of Health and
Human Services, CDC; 2013.
Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB,
et al. Risk of anaphylaxis after vaccination of children and adolescents.
Pediatrics. 2003 Oct;112(4):815-20.
Oberle D, Pavel J, Rieck T, Weichert S, Schroten H,
Keller-Stanislawski B, et al. Anaphylaxis After Immunization of Children and
Adolescents in Germany. Pediatr Infect Dis J. 2016 May;35(5):535-41.
Rouleau I, De Serres G, Drolet JP, Skowronski DM, Ouakki M,
Toth E, et al. Increased risk of anaphylaxis following administration of 2009
AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. Vaccine. 2013
Dec 05;31(50):5989-96.
Des Roches A, Paradis L, Gagnon R, Lemire C, Begin P, Carr S,
et al. Egg-allergic patients can be safely vaccinated against influenza. J
Allergy Clin Immunol. 2012 Nov;130(5):1213-6 e1.
Des Roches A, Samaan K, Graham F, Lacombe-Barrios J, Paradis
J, Paradis L, et al. Safe vaccination of patients with egg allergy by using
live attenuated influenza vaccine. J Allergy Clin Immunol Pract. 2015
Jan-Feb;3(1):138-9.
Turner PJ, Southern J, Andrews NJ, Miller E,
Erlewyn-Lajeunesse M, Investigators SS. Safety of live attenuated influenza
vaccine in atopic children with egg allergy. J Allergy Clin Immunol. 2015
Aug;136(2):376-81.
Turner PJ, Southern J, Andrews NJ, Miller E,
Erlewyn-Lajeunesse M, Investigators S-S. Safety of live attenuated influenza
vaccine in young people with egg allergy: multicentre prospective cohort
study. BMJ. 2015 Dec 08;351:h6291.
Turner PJ, Erlewyn-Lajeunesse M. Intranasal live-attenuated
influenza vaccine (LAIV) is unlikely to cause egg-mediated allergic reactions
in egg-allergic children. J Allergy Clin Immunol Pract. 2015
Mar-Apr;3(2):312-3.